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ABSTRACT 
Recent findings suggest that malignant neoplasms are derived from a small 
sub-population of cells that acts as the "root" of tumours. This conclusion 
comes from the observation that when neoplastic cells of  different types were 
tested for their growth potential both by in vitro and in vivo experiments, only a  
restricted minority of them displayed extensive proliferation. These cells are 
called cancer stem cells (CSCs): both anti-cancer drugs and irradiation cause 
cancer cells to die by apoptosis, however CSCs might survive and regenerate 
cancer. At present, CSCs theory represents a breakthrough in cancer 
research. The aim of this project is to characterize the protein expression 
pattern of CSCs to obtain further insights into the mechanisms of this class of 
cells. The knowledge of deregulated proteins could be the first step into the 
accomplishment of novel therapies targeted directly against CSCs. Particularly, 
we studied colon CSCs by using as experimental model two different colon 
cancer cell line systems: CaCo-2 and HCT-116. Putative CSCs were 
separated from non-CSCs by flow cytometry using CD133 as stemness 
marker. Then, total protein extract of CD133+ cells was compared to protein 
extract of CD133- cells and differentially expressed proteins were identified by 
2D DIGE coupled with tandem mass spectrometry. Forty-nine differentially 
expressed proteins in CaCo-2 CD133+ vs CD133- cells and thirty-six in HCT-
116 CD133+ vs CD133- cells were identified.  Bioinformatics analysis of the 
differentially expressed proteins by using GeneOnthology and Ingenuity 
Pathway Analysis (IPA) software showed an alteration of energy metabolism, 
furthermore the examination of this network showed that several proteins were 
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directly or indirectly connected to MCC (mutated in colorectal cancer), a 
negative regulator of Wnt pathway. Interestingly, among the identified proteins 
it has been observed a 2-fold change up-regulation of the splicing factor 
SRp20, newly identified target gene of the Wnt/β-catenin pathway and we 
demonstrated a direct cause-effect relationship between Wnt pathway 
activation and the increased level of SRp20 expression. Furthermore, the 
results of this work show that SRp20 influences cell proliferation thus 
suggesting a putative function of this protein in tumorigenicity of CD133+ cells. 
In conclusion, the activation of the Wnt pathway in CD133+ cells and the 
consequent up-regulation of SRp20, which is implicated in tumorigenesis, 
raises the possibility of a sequential series of molecular events occurring in 
connection with this process. 
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1. INTRODUCTION 
 
1.1 Cancer stem cells 
Stem cells are distinguished from other cell types by two important 
characteristics. First, they are unspecialized cells capable of renewing 
themselves through cell division, sometimes after long periods of inactivity. 
Second, under certain physiologic or experimental conditions, they can be 
induced to become tissue or organ specific cells with special functions. One 
strategy by which stem cells can accomplish these two tasks is asymmetric cell 
division (Fig.1), whereby each stem cell divides to generate one daughter with 
a stem-cell fate (self-renewal) and one daughter that differentiates.  
 
 
 
Recently, another class of stem cells have been identified: cancer stem cells 
(CSCs). Although the idea of CSCs has been proposed for a number of 
decades, demonstration of their existence has only occurred within the last ten 
 9 
 
years. Advances in CSC isolation were first achieved in hematological 
malignancies, with the first CSC demonstrated in acute myeloid leukemia [1]. 
However, using similar strategies and technologies, and taking advantage of 
available surface markers, CSCs have been more recently demonstrated in a 
growing range of epithelial and other solid organ malignancies [2-4], including 
colorectal cancer [5-7] suggesting that the majority of malignancies are 
dependent on such a compartment. It is still unclear what is the origin of these 
cells: they may arise from normal stem cells, partially differentiated progenitor 
cells or fully differentiated cells (Fig.2) [8]. Certainly, normal stem cells, since 
they have a long lifespan, they have more opportunities to accumulate 
mutations leading to malignant transformation.  
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Subsequently, after the CSCs isolation, a new cancer model has been 
proposed, in addition to the old stochastic model, to explain tumour 
development: the so called CSCs model or hierarchical model (Fig.3). 
According to the stochastic model, tumour cells are biologically equivalent but 
their behaviour is influenced by intrinsic and extrinsic factors and is both 
variable and unpredictable. Therefore, tumour-initiating activity cannot be 
enriched by sorting cells based on intrinsic characteristics. Hence the 
stochastic model (Fig.3A) assumes that every tumour cell is capable of 
initiating tumour growth and if it acquires a set of somatic mutations can 
develop metastatic capacity. In this case, all cancer cells must be eliminated to 
cure the patient. Conversely, the hierarchical model (Fig.3B) postulates the 
existence of biologically distinct classes of cells with differing functional abilities 
and behaviour and proposes that only few cells, the CSCs, are able to initiate 
and sustain tumour growth and to spread throughout the body, forming new 
tumours at distant sites [9].  
 11 
 
 
 
Although CSCs are similar to normal adult stem cells, they have a set of 
several features that cause physiologic disarray: angiogenesis, invasion, 
metastasis and resistance to apoptosis with their cellular division that is driven 
by internal cellular events regardless of external stimuli [10]. Moreover these 
cells have a slower rate of division and greater ability to correct DNA defects 
than other cells. Therefore, CSCs are more resilient to adjuvant therapy 
promoting the evolution of resistant clones that persist and even if the bulk of 
the tumour is destroyed by chemotherapy or radiotherapy, the tumour will 
reoccur. Conventional therapies may shrink tumours by killing mainly cells with 
limited proliferative potential. If the putative cancer stem cells are less sensitive 
to these therapies, then they will remain viable after therapy and re-establish 
the tumour. By contrast, if therapies can be targeted against cancer stem cells, 
then they might more effectively kill the CSCs, rendering the tumours unable to 
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maintain themselves or grow (Fig. 4). Thus, even if CSCs-directed therapies do 
not shrink tumours initially, they may eventually lead to cures. To target CSCs, 
it is important to identify their regulatory mechanisms and signalling pathways. 
 
 
1.2 Colon cancer stem cells 
Colorectal cancer (CRC) is the third most common form of cancer and the 
second cause of cancer related death in the Western world, leading to 655,000 
deaths worldwide per year [11]. It derives from an imbalance in proliferation 
and differentiation of the epithelium and apoptosis. When proliferation is no 
longer balanced from apoptosis, benign protrusions, called polyps, arise into 
the colon lumen. These polyps may develop into malignant cancers as CRC.  
The intestinal tract consists of the small intestine (duodenum, jejunum and 
ileum) and the large intestine or colon. The absorptive epithelium of the small 
intestine is ordered into villi and crypts of Lieberkühn. Differentiated cells 
(enterocytes, enteroendocrine cells and goblet cells) occupy the villi. A fourth 
differentiated type, the Paneth cells, functionally similar to neutrophils, resides 
 13 
 
at the bottom of crypts only in the small intestine epithelium and secretes 
antimicrobial agents. The remainder of the crypts constitutes the 
stem/progenitor compartment. As shown in figure 5, putative stem cells (dark 
blue) reside immediately above the Paneth cells (yellow) near the crypt bottom, 
proliferating progenitor cells occupy the remainder of the crypt, differentiated 
cells (green) populate the villus, and include goblet cells, enterocytes and 
enter-endocrine cells [12]. As shown in figure 6, the mucosa of colon has a flat 
surface epithelium instead of villi and putative stem cells (dark blue) reside at 
the crypt bottom, proliferating progenitor cells occupy two-thirds of the crypt, 
differentiated cells (green) populate the remainder of the crypt and the flat 
surface epithelium. The terminally differentiated cells, which are found in the 
top third of the crypt, are continually extruded into the lumen. In fact, within 4-8 
days, these differentiated cells die of apoptosis [13] and are replaced by other 
differentiated cells that derive from multipotent stem cells located at the bottom 
of the crypt in a ‗niche‘ encased by intestinal subepithelial myofibroblasts 
(ISEMFs) separated only by the basal lamina. The ISEMFs form a syncytium 
within the lamina propria that extends along the length of the intestinal tract 
(Mc Donald et al., 2006; Radtke et al., 2005) [14,15]. This syncytium secretes a 
variety of cytokines that are important for wound healing and immune cell 
function. Furthermore, they control the proliferation and differentiation of the 
epithelial cells and play a role in electrolyte and water absorption. In 
pathological states, ISEMFs contribute to fibrosis, desmoplastic reactions and 
neoplasia [16].  
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During asymmetric division, the stem cells undergo self-renewal and generate 
a population of transit-amplifying cells that, upon migration upward the crypt 
proliferate and differentiate into one of the epithelial cell types of the intestinal 
wall and occupy the lower two thirds of the crypt. Although crypts are 
monoclonal, each villus receives cells from multiple crypts and is therefore 
polyclonal [17,18]. Existence of CSCs in colon cancer has been reported in 
2007 by different research groups [5-7].  
Symmetric division of colon CSCs is essential in achieving exponential 
numbers of tumour cells [19]. As mentioned above, the differentiated cells of 
colonic mucosa have a short lifespan of few days, whereas normal intestinal 
stem cells have a long lifespan and capacity to self-renew and therefore they 
have more opportunity to accumulate tumorigenic mutations [15]. These 
mutations are accompanied by phenotypic change in the mucosa. A new 
evidence suggests that the long-lived adult colonic stem cells can accumulate 
mutations for a prolonged period of time before phenotypic change becomes 
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apparent [20, 21]. The hypothesis of stem cell-driven tumourigenesis in CRC 
has received substantial support from the recent identification and phenotypic 
characterization of a subpopulation of colon cancer cells able to initiate tumour 
growth and to reproduce human colon carcinomas faithfully in mice. 
The identification, isolation, and characterization of colon stem cells (SCs) is 
very difficult. Many obstacles have interfered with the identification of intestinal 
SCs among which the complexity of the crypt structure that limits the retrieval 
of putative SCs from their niche where they are interspersed among more 
differentiated daughter cells. Several studies have attempted to identify 
intestinal SCs within colonic crypts by using indirect techniques based on 
biological features restricted to the stem cell compartment. Long term retention 
of label DNA has been exploited as surrogate marker of stemness based on 
the observation that SCs in adult tissues usually divide at a slow rate when 
compared to the progenitor population [22]. This functional difference is 
highlighted by labelling the genetic material of proliferating cells in mouse 
intestinal crypts with tritiated thymidine [23] or by the administration of the 
DNA-labelling dye bromodeoxyuridine to rats in drinking water [24]. These 
approaches have allowed the identification of low mitotic index cells that 
undergo only limited dilution of label over time and are located at the bottom of 
the crypts. Only recently new methods have arisen to aid in the identification 
and isolation of CSCs. The most important of these has been the identification 
of surface markers by immuno-histochemistry. Other methods of identification 
include morphological features such as ‗bell shaped‘ nuclei and their position at 
the base of the crypt [25]. 
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The CSC population is defined by fluorescence-activated cell sorting (FACS) of 
tumour cells according to the expression of ‗signature‘ cell surface biomarkers. 
Proposed biomarkers include CD133 [26-28], CD44 [29-31], CD34 [1,32], 
CD24  and epithelial-specific antigen (ESA) [29,30]. Injection of CSC-enriched 
populations into immunodeficient mice at low concentrations results in the 
formation of tumours with equivalent histology and phenotypic heterogeneity to 
the original neoplasm, whereas injection of non-CSCs, even at high 
concentrations, results in the growth of few or no tumours [26, 29-31]. 
Research so far suggests that the molecular ‗signature‘ which specifically 
identifies CSCs is likely to constitute a combination of cell surface proteins that 
are co-ordinately expressed or repressed. The CD44, CD166, CD133 and 
EpCAM (epithelial cells adhesion molecule) are markers of tumorigenic cell 
population of colorectal cancer.  
 
1.3 CD133  
One of the main CSC markers identified was CD133, a pentaspan 
transmembrane glycoprotein also known in humans as Prominin 1 [33]. The 
CD133+ population is enriched in cancer-initiating cells in many tissues, 
including retinoblastoma [34], brain tumor [26,35], kidney cancer [36], prostate 
tumor [27], hepatocellular [37] and colon carcinomas [6,7]. Nonetheless, use of 
CD133 as a marker for identification and isolation of colon CSCs is a subject of 
debate; despite its use in isolating cell populations with cancer-initiating ability, 
studies have shown that CD133 is expressed by stem cells (SCs) and more 
differentiated progenitor cells [38]. CD133‘s function is unclear, although it is 
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believed to have a role in asymmetric division and self-renewal. Bauer et al 
proposed that the polarized localization of CD133 indicates its role in regulating 
proliferation [39]. CD133 is concentrated in cell surface domains that 
correspond to the spindle pole region during metaphase. In telophase and 
cytokinesis, it is either equally or unequally distributed between the 2 nascent 
daughter cells. Studies have indicated a role for CD133 in tumor angiogenesis. 
CD133+ glioma cells produce proangiogenic factors that can directly modify 
endothelial cell behaviour [40]. Other data indicate that the CD133+ cell 
population can itself give rise to endothelial cells that promote vascularization 
and tumor growth, like renal progenitor cells do [41]. Within the intestine, 
CD133 would mark SCs susceptible to neoplastic transformation. These cells 
would be in fact prone to aberrantly activate Wnt signaling and such event 
would disrupt normal tissue maintenance leading to their aberrant expansion, 
resulting ultimately in neoplastic transformation of the intestinal mucosa [42]. 
The existence of colon CSCs was first reported by the research groups of John 
Dick and Ruggero De Maria [6,7] which independently described a small 
population of cancer cells capable of initiating tumor growth in immunodeficient 
mice. By implanting limiting dilutions of human colon cancer cell suspensions 
into pre-irradiated non-obese diabetic severe combined immunodeficient mice, 
O‘Brien et al demonstrated that only a small subset of colon cancer cells 
(1/5.7x104 total cells) initiated tumor growth. Using flow cytometry, Ricci- Vitiani 
et al detected a rare population of CD133-/cytokeratin CK20- cells in colon 
tumor samples (2.5% ±1.4% of total cells). CK20 is considered a colonic 
epithelial terminal differentiation marker and therefore to be absent in the SC 
compartment. Based on immunohistochemical analyses, these cells were 
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present in areas of high cell density. The tumorigenic potential of colon CD133- 
cells was next analyzed by comparing the ability of CD133+ and CD133- 
populations to engraft and give rise to subcutaneous tumors in severe 
combined immunodeficient mice (Fig. 5). Low numbers of CD133+, but not 
high numbers of CD133- engrafted and formed tumors; high numbers of 
unsorted cells gave rise to tumors but, despite the high number of CD133- 
among them, tumor formation took more time. 
 
 
1.4 Proteomics and its impact on the life sciences 
Genomics is the comprehensive analysis of the genetic content of an 
organism. It also often refers to genome wide studies of mRNA expression. 
Already during the ―genomic era‖ that ended with the sequencing of Human 
Genome in the year 2003, the scientific community realized that the 
identification of coding sequences is insufficient to understand the molecular 
mechanisms of cell activity. Therefore, the attention increasingly focused on 
the products of the genome: the proteins and enzymes that determine cellular 
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architecture and function. The Proteome is the protein complement of the 
genome. According to the current annotation, the human genome consists of 
about 25000 genes, scattered among 3 billions nucleotides of chromosome-
based DNA code [43]. This represents a huge amount of static information, 
which needs to be correlated with dynamic information coming from gene 
products and their interactions. In contrast to the genome, the proteome is 
dynamic and is constantly modulated because of a combination of factors, 
which include mRNAs differential splicing, post translational modifications 
(PTMs), temporal and functional regulation of gene expression as well as the 
formation of multi-protein complexes. More than 100 modification types are 
recorded and additional ones are yet to be discovered [44]. All modified forms 
from one protein can vary in abundance, activity or location inside a cell. 
Indeed, cellular proteins are not invariant products of genes, but are subject to 
a high degree of interdependent processing at the protein level that is a critical 
component of cellular function and regulation. In addition, protein expression is 
dynamically regulated in response to external and internal perturbations under 
developmental, physiological, pathological, pharmacological and aging 
conditions. In fact, in contrast to the static genome, where all information could 
in theory be obtained from the DNA of a single cell, the proteome is considered 
dynamic because highly dependent not only on the type of cell, but also on the 
state of the cell [45]. Proteomics provides methods for correlating the vast 
amount of genomics information that is becoming available with the equally 
vast protein information that is being produced through analysis of cells under 
normal versus altered states [46]. In the last few years proteomics has become 
a powerful tool for the investigation of complex biochemical processes and 
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protein-protein interactions [47-48]. In medical sciences, proteomics has 
manifested significant impact on various aspects of clinical research, including 
understanding of disease pathogenesis, discovery of novel biomarkers for 
early disease diagnosis as well as identification of new drug and vaccine 
targets [49–52]. The biomarkers are biomolecules that are used to aid in 
monitoring disease progression and following prognosis in response to the 
therapeutic interventions. Identification of protein biomarkers is useful for early 
detection of various fatal diseases such as cancer or autoimmune disorders 
and has significant impact on human health [53, 54]. 
 
1.5 Proteomics analysis 
The term Proteomics is associated to the set of analytical tools used to depict 
the protein compartment of a cell. It is the natural continuation of Genomics 
approach and it moves away from classical Protein Chemistry, taking 
advantages of all the heritage of knowledge and methods developed from the 
latter. The great innovation of the Proteomics analysis is in fact the idea that to 
study the cellular molecular mechanisms, in which proteins play a key role, it is 
necessary to study the entire proteome as a ―single analyte‖ this means that, 
the proteins target of the analysis are no more purified and isolated from their 
highly complexity context found in living systems. Indeed, they are analyzed all 
together in order to obtain a real snapshot of the proteome, related to a 
particular cell state. From this general definition it is possible to distinguish two 
main areas of interest: i) ―expression proteomics‖ that is focused on the 
characterization of the change in protein expression levels and eventually the 
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definition of PTMs [55], ii) ―functional proteomics‖ aimed to understand protein-
protein interactions [56], signal pathways [57] and structure function relations. 
However, the proteome analysis is hindered by several analytical problems. 
First of all is the large range of protein concentration present in the samples. 
For example, in the human serum the 50 most abundant proteins represent 
about 99% of the total amount of protein mass but only less than 0.1% in 
number [58]. Another important challenge is surely the detection of PTMs. In 
fact only a minor part of the proteins of interest are post translationally 
modified. The high sample complexity, in terms of number of analytes, is also a 
feature that has to be taken in account, in fact for about 21000 human protein 
encoding genes are estimated around 106 human proteins [59]. For these 
reasons the Proteomics analysis needs a pool of methodologies and 
technologies that are high throughput, sensitive, selective toward the proteins 
target of the analysis and with large dynamic range effectiveness. Currently, 
Proteomics may rely on many chromatographic and electrophoresis tools to 
fractionate the analytes. However, if different approaches are in relation to 
these techniques of separation, all the strategies have a common essential 
final step: the mass spectrometry (MS) analysis of peptides or proteins. In the 
following section the expression proteomics employed for the purposes of this 
PhD  programme will be covered in more detail. 
 
 
 
 22 
 
1.5.1 Expression proteomics 
Mammalian cells contain thousands of different proteins and only a small 
number of them changes under such circumstances. The primary goal of 
expression proteomics is to detect differences in protein expression patterns 
between normal and diseased tissue. Proteome analysis bases on two 
essential components: protein separation and protein identification. Historically, 
the tool of choice for maximal separation of proteins was two-dimensional 
electrophoresis (2-DE) that relies on separating proteins based on their 
isoelectric point (pI) and molecular weight (MW) (Fig. 8). 
 
 
 
Proteins carry a negative, positive or zero net charge depending on their amino 
acid composition and covalent modification (such as phosphorylation, 
nitrosylation, sulphation and glycosylation), and the pH of the environment. The 
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pI of a protein is the pH at which the protein carries no net charge. If the 
proteins migrate in a pH-gradient, they will move until they reach a position in 
the pH-gradient where their overall net charge is zero, i.e. the pH is equal to 
the pI of the protein. The original 2DE method, described by O‘Farrell (1975) 
[60], used carrier ampholytes in tube gels to create and maintain a pH-
gradient. Carrier ampholytes are small amphoteric molecules with high 
buffering capacity near their isoelectric points and are usually employed as 
mixtures covering a set pH range. When an electric field is applied across a 
mixture of carrier ampholytes the most negatively charged proteins move 
towards the anode and the most positive ones towards the cathode. In this way 
it is possible to form a continuous pH-gradient within a gel, which is suitable for 
focusing larger amphoteric molecules such as proteins. However, this method 
had limitations in the resolving power and in the pH gradient stability. Several 
innovations significantly improved reproducibility and performance of the first 
dimension focusing step (IEF) in 2D-PAGE such as commercially available 
immobilized pH gradient strips, in which the carrier ampholytes are co-
polymerised into the gel matrix. Furthermore, the gel is cast onto a plastic 
support strip making the system much more robust and easier to handle. The 
second dimension uses the traditional SDS-PAGE technique; the IEF strip 
replaces the stacking gel. Despite being a well-established technique for 
protein analysis, traditional 2D gel electrophoresis is time-consuming and 
labour-intensive. Nevertheless, in 2-DE there are sources of variability that can 
distort the real difference in protein expression: a) analytical variations due to 
treatment of the sample, to procedures for staining or to image acquisition; b) 
biological variations due to environment in which the sample was produced, 
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processed and preserved. To minimize these variations, it is useful to work 
with multiple biological and analytical replicates thus increasing the difficulty of 
analysis (Fig.9). 
 
 
1.5.2 2D-DIGE 
The development of 2-D differential in-gel electrophoresis (2D- DIGE) in 1997 
overcame this limitation by allowing up to three distinct protein mixtures to be 
separated within a single 2D-PAGE gel [61]. In a typical 2D-DIGE experiment, 
proteins extracted from three different samples, healthy, diseased and internal 
control (a pooled sample formed from mixing equal amounts of the proteins 
extracted from the healthy and diseased samples), are covalently labeled, 
each with a cyanine fluorescent dye that has a different excitation and 
emission wavelength. The ability to multiplex different cyanine dye labelled 
samples on the same gel means that the different samples will be subject to 
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exactly the same 1st and 2nd dimension running conditions. Consequently the 
same protein labeled with any of the dyes and separated on the same gel will 
migrate to the same position on the 2D gel and overlay. This limits 
experimental variation and ensures accurate within-gel matching. The used 
cyanine dyes are: 1-(5-carboxypentyl)- 1′-propylindocarbocyanine halide N-
hydroxysuccinimidyl ester (Cy3); N 1-(5-carboxypentyl)-1′-
methylindodicarbocyanine halide N-hydroxysuccinimidyl ester (Cy5); and 3-(4-
carboxymethyl)phenylmethyl- 3′-ethyloxacarbocyanine halide N-
hydroxysuccinimidyl ester (Cy2) (Fig. 10). Equal concentrations of the 
differentially labeled proteomes and of the control sample are mixed, applied to 
a single gel plate, and separated using 2D-PAGE. The control sample serves 
as an internal standard, enabling both inter- and intra-gel matching. The control 
sample should contain every protein present across all samples in an 
experiment. This means that every protein in the experiment has a unique 
signal in the internal standard, which is used for direct quantitative 
comparisons within each gel and to normalize quantitative abundance values 
for each protein between gels. Scanning the gel at the specific excitation 
wavelengths of each dye, using a fluorescence imager, allows visualization of 
the differentially labeled proteins. The images are then merged and analyzed 
using imaging software, which enables differences between the abundance 
levels of proteins to be compared.  
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To compare protein expression across a range of experimental samples and 
gels, two distinct steps are required during the image analysis (Figure 11): a) 
intra-gel co-detection of sample and internal standard protein spots and b) 
inter-gel matching of internal standard samples across all gels within the 
experiment. In the first step three scans are made of each gel, Cy2, Cy3 and 
Cy5 scans. Scanned images of each sample and the internal standard are 
overlaid by a software. The algorithms within the software co-detect the spots 
present in each scan-image, effectively identifying the position of each spot 
within the gel (Figure 11a). In this way every protein in the sample is 
intrinsically linked to the corresponding protein spot in the internal standard 
sample. In the second step, the inter-gel comparisons of spot abundance are 
carried out. Following co-detection, each image has a spot map species. The 
internal standard image with the most detected spots is assigned as the 
'Master'. The spot map species for the internal standard assigned as the 
Master, is used as a template to which all remaining spot map species for the 
other internal standards (intrinsically linked to their co-detected sample 
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images) are matched (Figure 11b). Once the protein spots have been 
matched, the ratio of protein abundance between samples can be determined. 
 
 
Spot volume (i.e. the sum of the pixel values within a spot minus background) 
for each experimental sample is compared directly to the internal standard by 
the software. Spot volume ratios are calculated indicating the change in spot 
volume between the two images. The protein abundance for each spot in each 
sample is then expressed as a (normalized) ratio relative to the internal 
standard. Statistical tests such as the Student‘s t-Test can then be applied to 
the data-software. The statistical tests verify that any change between the 
groups is significant and give the user a level of confidence by taking into 
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account the inherent biological variation within a group compared to the 
induced difference between groups. It assigns a confidence rating as to 
whether this change is above the biological variation. Concluding, the 
introduction of 2D-DIGE contributed immensely to solving problems of 
reproducibility and quantization. The use of imagers and computers allows not 
only fast data mining, acquisition, and analysis but also spot detection, 
normalization, protein profiling, background correction, reporting and exporting 
of data. As a separation, detection and quantization technique, 2D-DIGE is an 
important tool especially for clinical laboratories involved in the determination 
of protein expression levels and disease biomarker discovery. When absolute 
biological variation between samples is the main objective, as in biomarker 
discovery, 2D-DIGE is the method of choice. 
 
1.6 Mass spectrometry tools for proteomic analysis 
-Principles and instrumentation- 
Whatever the used proteomic approach, the common essential final step of a 
proteomic experimental workflow is the mass spectrometry (MS) analysis. 
Mass spectrometers consist of three basic components: an ion source, a mass 
analyser, and an ion detector. Molecular mass measurements are carried out 
indirectly, calculating the mass charge ratio (m/z), by the analysis of kinetics 
behaviour of the ionized analytes in the gas phase and in electromagnetic 
fields. The need of a method that transfers efficiently intact molecules from 
solution or solid phase into the gas phase, was the limit that for many years 
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excluded proteins and peptides from this powerful technique. With the 
development and the commercialization of mass spectrometers based on the 
ion source technologies of ―Matrix-Assisted Laser Desorption/Ionisation‖ 
(MALDI) [62] and ―Electrospray Ionisation‖ (ESI) [63] the gas phase ionization 
of polar analytes has also become possible. Both MALDI and ESI are 
considered as soft ionisation techniques with which the generated ions 
undergo little or none fragmentation. In MALDI technique, samples are co-
crystallised with a weak aromatic acid matrix on a metal target. A pulsed laser 
is used to excite the matrix, which causes rapid thermal heating of the 
molecules and desorption of ions into the gas phase in a pulsed beam fashion. 
After the laser activation, the weak acid nature of the matrix drives to generate 
single-charged ions in the form of MH+ adduct (Fig.12). The one-one analyte-
MS signal relation in MALDI-MS makes possible to analyze also multi-
component mixtures without any interpretation difficulties caused by the peaks 
overlapping. 
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ESI creates ions by spraying an electrically generated fine mist of ions into the 
inlet of a mass spectrometer at atmospheric pressure. By creating a potential 
difference between the capillary, through which the liquid flows, and the inlet of 
the mass spectrometer, small droplets of liquid are formed. These are 
transferred into a heated device to induce efficient evaporation of solvent. 
Once the droplets have reached the Rayleigh limit, ions are desorbed from the 
droplet generating gas-phase ions in a continuous beam fashion (Fig.13). The 
ions produced by ESI sources are multiply charged adducts MHn
n+, where the 
number of protons incorporated depends on the statistical acid/basic 
equilibrium of the analytes. This situation complicates the spectra interpretation 
because each analyte may give rise to many signals in the spectrum. For this 
reason it is not possible to analyze complex mixture without a previous 
fractionation. However, because the ionization is carried on a liquid flow, ESI 
source may be simply coupled to liquid chromatography systems.  
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The most notable improvement of ESI technique has come from the reduction 
of the liquid flow rate used to create the electrospray to nano-scale level. 
Nano-sources create ions more efficiently [64] because the charge density at 
the Rayleigh limit increases significantly with decreasing droplet size. Another 
advantage of using separation techniques with nano-ESI is the increase in the 
concentration of the analyte as it elutes off the column. After ionisation, the 
analytes reach the mass analyzer, which separates ions by their mass-to-
charge (m/z) ratios. Ion motion in the mass analyser can be manipulated by 
electric or magnetic fields to direct ions to a detector, usually an electro-
multiplier, which records the numbers of ions at each individual m/z value 
converting the signals in current. In Proteomic research, four basic kinds of 
mass analysers are currently used: time-of-flight (TOF), ion trap (IT), 
quadrupole (Q), and Fourier transform ion cyclotron resonance (FTICR) 
analysers (Fig.14). All four differ considerably in sensitivity, resolution, mass 
accuracy and the possibility to fragment peptide ions. They are very different in 
design and performance, each with its own strength and weakness. These 
analysers can be stand alone or, in some cases, put together in tandem to take 
advantage of the strengths of each. 
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The quadrupole mass filter consists of a linear array of four symmetrically 
arranged rods to which radio frequency (RF) and DC voltages are supplied. 
Forces are exerted in a plane normal to the direction (z-direction) in which the 
ions drift. The RF potential gives rise to a field which alternatively reinforces 
and then dominates the DC field. Ions oscillate in the x,y-plane with 
frequencies which depend on their m/z values. If the oscillations of an ion in 
this plane are stable, the ion will continue to drift down the rod assembly and 
reach the detector. Stable oscillations are only achieved by ions of given m/z 
value for a given rod assembly, oscillation frequency, RF voltages and DC 
voltages. Commercially available instruments usually have mass/charge limits 
ranging from 0 to 4000 m/z and at best are normally set to resolve the various 
13C isotope peaks for a singly charged ion, although the resolution may be 
intentionally degraded to improve sensitivity. In ESI, multiple charging enables 
quadrupole mass measurement of molecules >100,000 Da, if the molecule can 
be charged sufficiently.  
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The ion trap consists of three electrodes, the central ring electrode and two 
end-cap electrodes of hyperbolic cross-section. In this device too, ions are 
subjected to forces applied by an RF field but the forces occur in all three, 
instead of just two, dimensions. In ion-trap analysers, ions are resonantly 
activated and ejected by electronic manipulation of this field. Ion traps are 
robust, sensitive and relatively inexpensive, and so have produced much of the 
proteomics data reported in the literature. A disadvantage of ion traps is their 
relatively low mass accuracy, due in part to the limited number of ions that can 
be accumulated at their point-like centre before space-charging effects distort 
their distribution and thus the accuracy of the mass measurement. 
Usually, in the Time-of flight (TOF) analyzers the ions are accelerated through 
a fixed potential into a drift tube. As all the ions with same charge obtain the 
same kinetic energy after acceleration, the lower m/z ions achieve higher 
velocities than higher m/z ions. Moreover, ion velocities are inversely related to 
the square root of the m/z. Thus, by measuring the time it takes to reach the 
detector, the m/z of the ion can be determined. Thanks to several strategies, 
such as delayed extraction of ions from the source, two stage sources with 
complex voltage gradients, and reflectron detectors, a commercial TOF 
instrument can typically achieve resolution of 10,000 or greater.  
A Fourier-transform ion-cyclotron resonance (FT-ICR) mass spectrometer (also 
referred to as a Fourier-transform mass spectrometer, or FTMS) uses a 
magnetic field to determine the m/z of an ion. In an FT-ICR ions have kinetic 
energies, at most, of a few tens of electron volts (eV). At low kinetic energies, 
ions are actually trapped under high vacuum in the magnetic field. For a 
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constant magnetic field, ions oscillate around the magnetic field with a 
cyclotron frequency that is inversely related to the m/z. In a very simplified view 
of FT-ICR, the cyclotron frequencies of the ions trapped in the FT-ICR are 
measured and then converted into m/z. State-of-the-art electronic equipment is 
capable of measuring frequencies with extremely high precision. This 
translates to a very high mass resolution, which is the property FT-ICR is most 
widely known for. Mass resolving power in the hundreds of thousands are fairly 
easy to obtain on instruments with large magnetic field strengths (that is, > 7 
Tesla), and resolutions in the millions have been demonstrated. Very high 
mass accuracies, down to the ppm level, can also be obtained (resolution 
>2,000,000). 
- Tandem MS - 
The power of mass spectrometry can be dramatically increased by employing 
methods of tandem mass spectrometry. Conventional MS produces ions that 
are separated by m/z and analyzed directly. If a soft ionization method is used, 
the mass spectrum will lead to calculate the molecular weight values of 
compounds present in the analyte but with little or no structural information. In 
a tandem MS (MS/MS) experiment, the first mass analyzer (MS1) is used to 
selectively pass an ion (precursor ion) into another reaction region where 
excitation and dissociation take place. The second mass analyzer (MS2) is 
used to record the m/z values of the dissociation products (daughter ions). 
Low-energy collision-induced (activated) dissociation (CID or CAD) [65] 
tandem mass spectrometry has been, by far, the most common method used 
to dissociate peptide ions for subsequent sequence analysis. Upon collisional 
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activation with a non-reactive gas, such as argon or helium, the amide bond of 
the peptide backbone will fragment to produce, ideally, a homologous series of 
b and y-type fragment ions (Fig.15). The observed fragmentation pattern 
depends on various parameters including the amino acid composition and size 
of the peptide, excitation method, time scale of the instrument, the charge state 
of the ion, etc. Peptide precursor ions dissociated under the most usual low-
energy collision conditions fragment along the backbone at the amide bonds 
forming structurally informative sequence ions and less useful non-sequence 
ions by losing small neutrals like water, ammonia, etc.  
 
 
Therefore, to achieve a multi-stage MS analysis many mass spectrometers 
equipped with hybrid combinations of analyzer have been built and are now 
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commercialized. Triple quadrupole (QqQ), quadrupole/ time of flight (QqTOF) 
and time of flight/ time of flight (TOFTOF) may perform ―space separated‖ 
tandem MS. Ion trap analyzer by itself may realize tandem MS experiments 
―time separated‖. This is accomplished by the expulsion of the ions trapped in 
MS mode, isolating the parent ion. This one is further fragmented by collision 
and the produced ions are first accumulated, then scanned and detected. This 
―time separated‖ operative mode allows to realize very sensitive MSn 
experiments with simple equipments. By using the above described MS tools, 
there are two different methods to identify proteins. The first method, usually 
obtained by MALDI-MS, is the “peptide mass fingerprinting” (PMF) [66] based 
on the idea that a protein digested by an enzyme with known specificity 
produces a peptides pool that may be used as discriminatory for its 
identification. MALDI-TOF analysis produces a unique spectrum giving the 
accurate monoisotopic mass of all the peptides produced by the protein 
digestion, producing peculiar molecular masses map for each protein. This 
map is then compared to the ones generated in silico by the virtual digestion of 
all the protein sequences present in a given interrogated database. The PMF 
method works well for isolated proteins, but the resulting protein identifications 
are not sufficiently specific for protein mixtures (e.g. for co-migrating proteins). 
The addition of sequencing capability to the MALDI method should make 
protein identifications more specific than those obtained by simple peptide-
mass mapping. In this case the second identification method ―MSMS ion 
search‖ should be implied. This method uses the MS tandem methodology and 
thanks to the peptide fragmentation, gives information about the amino acidic 
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sequence of the peptides (and so, of the proteins) in analysis. It is sufficient a 
sequence of 5-6 amminoacids to identify univocally a protein.  
 
1.7 Aim of the PhD thesis 
The aim of this study was to obtain insights into the colon cancer stem cells 
(CSCs) molecular mechanisms, in fact CSCs theory represents a breakthrough 
in the recent cancer research. As experimental model, we used a combined 
approach of flow-cytometry, differential proteomic and mass spectrometry on 
two different colon cancer cell line systems i.e. CaCo-2 and HCT-116 derived 
from tumors taken directly from patients. Flow-cytometry was employed to 
separate putative colon CSCs from non-CSCs according the expression of the 
universal recognized stem cell marker CD133. Then, a differential proteomic 
approach was used to compare total protein extracts of CD133+ cells (putative 
CSCs) to total protein extracts of CD133- cells (non-CSCs). Particularly, the 
innovative and powerful methodology of 2D-DIGE was applied to our samples. 
The protein spots differentially expressed in the two sub-population of cells 
were identified by mass spectrometry. Several selected proteins were validated 
by western blotting, the whole group of identified proteins for each cell line was 
submitted to bio-informatic analysis and finally, functional assays on selected 
proteins of interest were performed. In the following sections the results 
obtained during the four years of PhD programme will be illustrated in detail. 
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2. MATERIALS AND METHODS 
 
2.1 Cell cultures 
Three different colon adenocarcinoma-derived cell lines were used: CaCo-2, 
HCT-116 and HT-29, all available from the CEINGE Cell Bank (Naples, Italy). 
The CaCo-2 cell line was grown in Essential Minimum Eagle‘s Medium 
(EMEM, Sigma-Aldrich, Oakville, ON) supplemented with 10% Fetal Bovine 
Serum (FBS, Gibco, Carlsbad, CA), 1% ultraglutammine (Cambrex, East 
Rutherford, NJ), 1% non essential amino acids and 1% sodium pyruvate. HCT-
116 and HT-29 were propagated in McCoy‘S 5A (Sigma-Aldrich) medium 
supplemented with 10% FBS and 1% ultraglutammine. Adherent cells were 
detached using Trypsin-EDTA (Sigma-Aldrich) solution, floating cells were 
collected and Trypsin-EDTA was inactivated using complete culture medium. 
 
2.2 Immunophenotyping and flow cytometry experiment 
After detaching, cells were washed and reconstituted to a final concentration of 
10 x 106 cells/mL in 2% FBS/PBS. As preliminary step, we analyzed the 
intrinsic fluorescence of CaCo-2, HCT-116 and HT-29 by using unlabelled 
samples that act as control. Cells were subdivided in 5ml polystyrene tubes 
(Falcon, Becton Dickinson, San Jose, CA). Cell suspensions (50μL) were 
incubated with 5μL of each antibody for 30 minutes at 4°C. Cells were then 
washed with 1mL 2% FBS/PBS, re-suspended in 500μL 2% FBS/PBS and 
analyzed by flow cytometry. FACSAria cell sorter (Becton Dickinson), equipped 
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with four excitation lines (633nm, 488nm, 407nm and 375nm lasers), was 
employed for the analysis. FITC, PE, Per-CP, PE-Cy7 were analyzed on the 
488nm line while allophyco-cyanin was excited by the 633nm laser. The 
antibodies used in this study included CD133-PE and CD133-allophyco-cyanin 
(AC133 clone; Miltenyi Biotec, Auburn,CA). 
 
2.3 Gating strategies 
Cells were first gated on physical parameters (FSC and SSC) to exclude the 
majority of dead and apoptotic cells. Then, FSC-Area versus FSC-height 
profiles were used to identify single cells and to exclude doublets. CD133+ 
cells were gated in CD133 vs ―empty channel‖ dot plot and then were sorted 
and collected. The isolated cell pellets were stored at -80°C until further 
analysis. 
 
2.4 Sample preparation for 2D-DIGE analysis 
To obtain total protein extracts, cells were washed twice with cold PBS, 
centrifugated at 1000 rpm for 5 min and resuspended with a lysis buffer 
containing 7M urea, 2M thiourea, 30 mM Tris-HCl pH 8.5, 4% CHAPS (w/v), 1x 
Complete® EDTA free, containing a cocktail of protease inhibitors (Roche 
Applied Science, Indianapolis, IN, USA). Protein extracts were incubated at 
4°C for 5 min and than sonicated to disrupt the cells and to shear the DNA and 
RNA in the cell. Protein samples were cleared from cell debris by centrifugation 
at 14000 rpm at 4°C for 20 min and then purified using the 2-D Clean-up Kit 
 40 
 
(GE Healthcare, Piscataway, NJ, USA) following supplier's instructions. Protein 
samples were then resuspended in lysis buffer. In order to perform the reaction 
between the N-hydroxysuccinimidyl ester reactive group of the CyDye 
fluorochrome and the epsilon amino group of lysine residues of proteins, 
protein solution pH was adjusted to the value of 8.5. Protein quantification was 
performed with the 2-D Quant Kit (GE Healthcare) by reading protein 
absorbance at 480 nm. To perform a successful CyDyes labeling using the 
Ettan DIGE Manual, protein concentrations was adjusted between 5 and 10 
mg/ml of lysis buffer. 
 
2.5 Labeling efficiency and same same same tests 
The labeling efficiency of the samples with the CyDye DIGE Fluors was tested, 
before DIGE experiment, by performing the following reactions: 
- 50 μg of total protein extract for each cell line was labeled with 400 pmol of 
Cydye Cy5.  
- 50 μg of total E. coli protein extract, used as control, was labeled with 400 
pmol of Cydye Cy5.  
E. coli  was chosen because its protein extract has already been labeled 
successfully. Herein, the procedure applied on CaCo-2 is described, but the 
same experiments were performed on HCT-116. Labeling reactions were 
carried out in the dark on ice for 30 min before quenching with 1 l of a 10 mM 
L-Lysine solution for 10 min. Serial dilutions of 25 μg, 12.5 μg and 6.25 μg of 
CaCo-2 and E.coli protein lysates were made. Proteins were then resolved on 
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a one-dimensional SDS gel with a concentration of 12.5% polyacrylamide. The 
gel was than acquired at the Cy5 wavelength using the Typhoon 9400 imager 
(GE Healthcare) and processed and analyzed with Image Quant Analysis 
software (GE Healthcare) to verify that the labeling efficiency of the protein 
sample is comparable to the control.  
The ―same same same‖ test was performed to verify that none of the three 
Cydyes labels the same test sample preferentially. 50 μg of total CaCo-2 
protein extract was labeled with 400 pmol of each Cydye. Proteins were 
resolved on a 2D polyacrylamide gel (26x20 cm) by using an Ettan DaltTwelve 
system (GE Healthcare). After electrophoretic separation, gels were scanned 
using the Typhoon 9400 imager (GE Healthcare). Fluorescence-labeled 
proteins were visualized at the appropriate wavelength for Cy3, for Cy5 and for 
Cy2. Images were acquired with Image Quant Analysis software (GE 
Healthcare). The images were processed and analyzed by DeCyder v5.02 
software (GE Healthcare). The comparison of the volume of fluorescence for 
all spots allowed us to define a threshold. All variations under this threshold 
were not considerated.  
 
2.6 Labeling of protein extracts 
Protein extracts (50μg) from 4 different biological replicates of CD133+ and 
CD133- cells were separately labeled at pH 8.5 with 400pmol of Cy3 and Cy5, 
according to manufacturer‘s protocol. We found no appreciable differences 
between spot patterns and volumes of Cy3 and Cy5 labeled proteins (data not 
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shown). However, to avoid any possible differences due to staining 
effectiveness we crossed the dyes between the pairs of analyzed samples 
(Table 1). As internal standard we used a mixture containing equal amount of 
the eight lysates in analysis labeled with Cy2. Labeling reactions were stopped 
with 1mM lysine. Each Cy3/Cy5-labeled sample pair was mixed with a Cy2-
labeled pooled standard sample. The Cy2/Cy3/Cy5-labeled samples were run 
together on the same gel (Gels 1-4 in Table 1). 
 
Table 1. 2D-DIGE experimental design  
Gel  Cy3a (50 µg)  Cy5a (50 µg)  Cy2a (50 µg)  
1  CD133+ replicate 1  CD133- replicate 2  Pool standardb 
2  CD133+ replicate 2  CD133-  replicate 1  Pool standardb 
3  CD133- replicate 3 CD133+ replicate 4  Pool standardb 
4  CD133-  replicate 4 CD133+ replicate 3  Pool standardb 
 
 
2.7 2D separation of CD133+ and CD133- protein samples 
Protein samples, mixed as described in Table 1, were separated on 24-cm IPG 
strips with a 3-10 non linear pH range (GE Healthcare). Strips were rehydrated 
before use with 450µl of DeStreak rehydration solution, 0.5% pharmalyte and 
0.5% IPG overnight at room temperature. Usually 50µg of protein lysates from 
CD133+ cells, 50µg from CD133- cells (Cy3 or Cy5 labeled) and 50µg of 
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pooled standard (Cy2 labeled) were mixed and the final volume was adjusted 
to 450μL with sample buffer containing 7M urea, 2M thiourea, 4% CHAPS, 1% 
DTT and 1% pharmalyte (GE Healthcare). The strips were then transferred to 
the Ettan IPGphor system (GE Healthcare) for IEF. Samples were loaded on 
the strips by anodic cup-loading. The IEF was carried out for 18h for a total of 
60kV/h, 50μA/strip at 20°C, using the following protocol: 
      Step 1: 300 V for 4h 
      Step 2: from 300 V to 1000 V for 6 h 
      Step 3: from 1000 V to 8000 V for 3 h 
      Step 4: 8000 V for 5 h 
Then, proteins were reduced by equilibrating IPG strips for 15min in 0.5% DTT 
(w/v), 100mM Tris pH 8.0, 6M urea, 30% glycerol (v/v), 2% SDS (w/v). Proteins 
were then alkylated for 15min using the same buffer containing 4.5% (w/v) IAA. 
After the equilibration steps, the strips were over layered onto 10% 
polyacrylamide gels (20 x 24cm) and the second dimension was carried out for 
18h at 2W per gel using an Ettan Dalt Twelve system (GE Healthcare) until the 
bromophenol blue reached the bottom of the gel. 
An independent two-dimensional preparative gel for each cell line was run with 
the same condition applied for the analytical gels, using for each gel, 0.5 mg of 
protein extract from Caco-2 and HCT-116 cells, respectively. Preparative gels 
were washed with a fixing solution of 40% methanol, 10% acetic acid, 50% 
water for 3 h before overnight staining in SYPRO Ruby (Molecular Probes, 
USA) with gently agitation, in the dark.  
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2.8 Analysis of gel images 
The gels were scanned using a fluorescence scanner (Typhoon 9400, GE 
Healthcare) at 100 μm resolution. Fluorescence-labeled proteins were 
visualized at the appropriate excitation/emission wavelengths: 532/580 nm for 
Cy3, 633/670 nm for Cy5 and 488/520 nm for Cy2. Preparative gel images 
were acquired using the Typhoon imager at excitation/emission wavelengths of 
457/610 nm. All gels were scanned by using the same parameters, selected to 
prevent pixel saturation. 
The fluorescent images of the 2D-DIGE gels were analyzed using the DeCyder 
software suite, version 5.02 (GE Healthcare). For each gel, the overlapped 
images (Cy3, Cy5, Cy2) were imported into the DeCyder DIA (Difference In-gel 
Analysis) module to detect differentially expressed protein spots in each gel. In 
fact, protein spots were detected and quantified with the DIA module. The 
maximum number of estimated spots was fixed at 5000. In addition, DIA was 
used to detect spot boundaries and calculate spot volumes, normalized versus 
the volume of the corresponding spot present in the pool standard of the same 
gel. Protein spots that matched among the four gels were obtained using the 
BVA (Biological Variation Analysis) module. The Cy2 image containing the 
highest number of spots, was assigned as ―master gel‖. The spot boundary 
maps of the master image were used as template. Matching of protein spots 
across gels was performed automatically. 
A standard abundance for each spot was thus calculated thereby allowing 
inter-gel variations. Each spot intensity was then expressed as mean of 4 
standard abundances calculated for the four gels described in Table 1. Spot 
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intensities were then compared in the two used conditions: CD133+ and 
CD133- cells. Statistical significance of differences in spot intensity was 
determined by Student‘s t-test. Only protein spots with at least 1.20-fold 
change in volume (p≤0.05) after normalization were considered significantly 
altered. We verified the validity of these changes and accuracy of spot 
matching by manual investigation. 
 
2.9 Protein identification by MS 
Protein spots on preparative gels were chosen for excision on comparison with 
the analytical gel. Spots of interest were picked using an Ettan Spot Picker (GE 
Healthcare). Gel pieces were washed in 50mM ammonium bicarbonate and 
50% ACN and subsequently rehydrated in a modified trypsin (Sigma) solution 
(10 ng/µl) in 50 mM ammonium bicarbonate pH 8.5, at 4°C for 1 h. The 
enzymatic solution was then removed. A new aliquot of buffer solution was 
added to the gel particles and incubated at 37°C overnight. The supernatant 
was collected whereas gel pieces were subjected to another extraction in ACN 
at 37°C for 15 min. The supernatant fraction and samples obtained from 
extraction steps were pooled and dried in a vacuum centrifuge. The resulting 
peptide mixtures were resuspended in TFA 0,1% and analyzed on a Voyager 
DE-STR MALDI-TOF (Applied Biosystems, Framingham, MA) in positive ion 
reflectron mode, 20kV and a pulsed nitrogen laser (337nm). Samples were co-
mixed to an equal volume of 10mg/mL CHCA (70:30 ACN:0.2% TFA), spotted 
onto a stainless steel MALDI target plate and air-dried. The mass spectra ( m/z 
600-4000) appropriately calibrated were analyzed using the Data Explorer 
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software v4.0 (Applied Biosystems). Mass values were then used for database 
searching using the MASCOT (version 2.1) PMF search program 
(http://www.matrixscience.com) selecting NCBInr sept09 database (9656715 
sequences) (http://www.ncbi.nlm.nih.gov) and Homo sapiens as taxonomic 
origin of the samples. The search was performed using trypsin as proteolytic 
enzyme, one missed cleavage, cysteine as S-carboxyamidomethylcysteine, 
unmodified N- and C-terminal ends, partial methionine oxidation, putative pyro-
Glu formation by Gln and a peptide maximum mass tolerance of 100ppm. 
Protein spots not identified during the PMF, were further analyzed by μLC-
MS/MS using the LC/MSD Trap XCT Ultra (Agilent Technologies, Palo Alto, 
CA, USA) equipped with a 1100 HPLC system and a chip cube (Agilent 
Technologies). After loading, the peptide mixture (7µl in 0.2% HCOOH ) was 
concentrated and washed at 4 µl/min in 40nl enrichment column (Agilent 
Technologies chip), with 0.1% HCOOH as the eluent. The sample was then 
fractionated on a C18 reverse phase capillary column (75µm x 43mm) at 
200nl/min with a linear gradient of eluent B (2% HCOOH in ACN) in eluent A 
(2% HCOOH) from 5% to 60% in 50min. Peptides were analyzed using data-
dependent acquisition of one MS scan (mass range 400-2000m/z) followed by 
MS/MS scans of the three most abundant ions. Dynamic exclusion was used to 
acquire a more complete range of the peptides by automatic recognition and 
temporary exclusion (2 min) of ions from which definitive mass spectral data 
had previously been acquired. Moreover a permanent exclusion list of the most 
frequent peptide contaminants (keratins and trypsin doubly and triply charged 
peptides) was used. For MS/MS data, the search was performed by using 
MASCOT with a peptide tolerance of 300 ppm and the following additional 
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criteria: maximum fragment mass tolerance of 0.6 Da, 2+ and 3+ charged 
peptides. Identifications were accepted taking in account three issues: 
significant MASCOT Mowse scores, spectrum annotation and expected 
migration on 2D gel. A MASCOT score of 64 corresponds to p<0.05 for PMF 
experiments, while a MASCOT score of 41 corresponds to p<0.05 for MS/MS 
sequencing. These thresholds were chosen as cut-off for a significant hit. 
 
2.10 Western Blot Analysis 
CD133+ and CD133- protein extracts (25µg) from three independent cultures 
were resolved on a 10% SDS-PAGE gel and then transferred onto 
nitrocellulose membranes (GE Healthcare). The membranes were blocked in 
5% non-fat milk in PBS pH 7.5 for 2h and incubated over night at 4°C with 1% 
milk/PBS pH 7.5 and 0.05% TWEEN containing specific commercial primary 
antibodies: mouse anti-SRp20 (1:200), anti-casein Kinase II (CKII) (1:200), 
anti-cytokeratin 8 (1:200), anti-catenin γ (1:200), anti-catenin β (1:200), anti-
annexinA2 (AnxA2) (1:200), anti-lamin A/C (1:200); rabbit anti-annexinA1 
(AnxA1) (1:200) and anti-Hsp27 (1:100) (Santa Cruz Biotechnology, 
Heidelberg, Germany). A mouse anti-Gapdh (1:1000, Sigma-Aldrich) antibody 
was used as loading control. The horseradish peroxidase (HRP)-conjugated 
anti-mouse (1:5000) and anti-rabbit (1:10000) secondary antibodies (GE 
Healthcare) were employed. Immunoblots were detected using the ECL-
Advance Western Blotting Detection kit (GE Healthcare) by 
chemiluminescence. Band volumes were normalized by using Gapdh as 
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control, visualized on the same film. Densitometric measurements were made 
using the Quantity One 4.5 tool (Biorad). 
 
2.11 Bioinformatic analysis 
Data were analyzed through the use of Ingenuity Pathway Analysis (IPA) 
software 7.0 (http://www.ingenuity.com). Drawing on published, peer-reviewed 
literature, IPA constructs networks of direct and indirect interactions between 
orthologous mammalian genes, proteins and endogenous chemicals. These 
relationships include those that occur due to disease and/or environmental 
input. This system can generate a set of networks with a maximum size of 35 
genes/gene products. Each network is characterized by a score computed 
according to the fit of the user‘s set of focus genes/gene products with all the 
genes/gene products stored in the knowledge base. The score is derived from 
a p-value (equal to or smaller than 0.05, Fisher's exact test) and indicates the 
likelihood of the focus genes/gene products in a network being found together 
due to random chance. Biological functions were then assigned to each 
network. Our data set was also analyzed by the GOstat software 
(http://gostat.wehi.edu.au/cgi-bin/goStat.pl) to identify significant biological 
pathways (GO terms). Searches were performed as follows: minimal length of 
the considered GO paths was 1, the maximal p-value was 0.01, no GO 
clustering was applied and Benjamini false discovering testing was used to 
correct for multiple testing. 
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2.12 Wnt/β catenin pathway stimulation 
CaCo-2 cell line was grown as described in paragraph 2.1. CaCo-2 cells were 
cultured with 100ng/ml recombinant human Wnt3a (R&D Systems, 
Minneapolis, MN). After 48h and 72h, cells were collected and protein extracts 
were obtained as described under section 2.4. The assay was performed on 
three independent replicates. 
 
2.13 RNAi and cell proliferation assay 
The SRp20 siRNA s12732, targeting a splice junction of SRp20 exon 2 and 
exon 3, was purchased from Ambion (Applied Biosystems). RNAi was 
conducted by transfection with 20 nM siRNA in the presence of Lipofectamine 
2000. The cells with silenced SRp20 were analyzed for protein expression by 
Western blotting and for tumor induction capability by proliferation assay. 
CaCo-2 siRNA transfected cells were detached from culture flask after 24h of 
incubation and seeded in flat bottom 96 well plate (BD-Falcon) at 5000 cells 
/well in DMEM:F12 (Sigma-Aldrich) w/o Phenol Red supplemented with 10% 
FBS, 2% Ultraglutammine. Cells were incubated at 37°C and 5% CO2 until 
120h after siRNA transfection. Cellular proliferation was measured daily by the 
use of WST-1 assay and colorimetric reaction was quantitated at 450–655nm 
with the Ultramark Plate Reader (Biorad) reagent according to manufacturer‘s 
instructions. The assay was performed on three independent biological 
replicates and for each point, the measure was performed on three technical 
replicates. 
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3. RESULTS  
 
3.1 Gating and sorting of CD133+ cells by flow-cytometry 
CD133+ cells were gated in CD133 versus an ―empty channel‖ dot plot for 
each cell line. As a preliminary step, we evaluated the intrinsic fluorescence of 
each cell line. Therefore, as control we used an unlabelled sample to evaluate 
the baseline fluorescence specific for the HCT-116, CaCo-2 and HT-29 cells 
(Figs. 16 A*, B* and C*). Finally, we selected CD133- cells, i.e., cells with the 
same level of fluorescence as unlabelled cells (control cells) and CD133+ cells, 
i.e., the cells with the highest level of fluorescence. In the HCT-116 cells, 80% 
are CD133+ cells and 20% are CD133- cells, which were spontaneously 
separated. In this case our strategy was to gate the brightest CD133+ cells 
(2% of total cells) and, as negative counterpart, we gated the whole population 
lacking CD133 (15-20%) (Fig. 16A). In the CaCo-2 and HT-29 cells, in which a 
large homogeneous population of cells uniformly expressed the antigen, we 
gated 2-5% of cells with the most intense staining. As negative counterpart we 
used 15-20% of the cells with the less intense CD133 staining (Figs. 16B and 
16C). Finally, we isolated and collected the selected cells. 
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3.2 2-DIGE analysis: labeling efficiency and same-same-same tests  
Prior to the DIGE experiment the labeling efficiency of the samples with the 
Cy5 dye was tested. To this aim, the labeling efficiency of CaCo-2 and HCT-
116 protein extract were compared with that of a control which has already 
been labeled successfully. The control was constituted by E. coli total protein 
extract. As shown in Figure 17 proteins were resolved on a one-dimensional 
SDS-PAGE gel, as described in the ―Materials and methods‖ section 
(paragraph 2.5). The gel was acquired at the Cy5 wavelength using the 
Typhoon imager and the relative images were processed and analyzed with 
the Image Quant Analysis software. The labeling efficiency was calculated as 
ratio between the average volumes of fluorescence of the sample with that of 
the control.  
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In addition, to verify that none of the three CyDyes labels the same test sample 
preferentially, the ―same same same‖ test was performed. By DeCyder 
software, the volumes of fluorescence for all spots of the sample labeled with 
Cy2 were compared with those labeled with Cy3 and Cy5, obtaining a similarity 
of labeling of 98% (Figure 18). The threshold was then set to 1.2 fold-change. 
All variations under this threshold were not considerate. 
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3.3 Identification of differentially expressed proteins by DIGE 
To learn more about colon CSCs, we measured the differential protein 
expression pattern of CaCo-2 and HCT-116 CD133+ and CD133- cells, using 
2-D DIGE. To increase biological and statistical significance of our results, we 
considered CD133+ and CD133- cells obtained from four independent 
cultures. About 2000 protein spots were detected in the analytical 2D gels for 
both cell lines. Fluorescence-labeled proteins in the 2D analytical gels were 
acquired at different wavelengths using an imager to generate an image 
specific for each CyDye. In this way three scans were made of each gel, Cy2, 
Cy3 and Cy5 scans. In the co-detection step scanned images of each sample 
were overlaid with the internal standard by the DIA module of the DeCyder 
software. By this way every protein in the sample was linked to the 
 54 
 
corresponding protein spot in the internal standard sample. Following co-
detection step, the matching of protein spots across the gels was performed 
using the BVA module of the DeCyder software. The spot map for the internal 
standard, with the most detected spots, was used as a template to which all 
remaining spot maps, for the other internal standards (intrinsically linked to 
their co-detected sample images), were matched. The spot volume, i.e. the 
sum of the pixel values within a spot minus background, for each experimental 
sample was directly compared, by the software, to the internal standard. By 
this way changes in the expression level of individual protein spots, expressed 
as ratio of protein abundance between CD133+ and CD133- cells, normalized 
to the internal standard, were identified. Each spot intensity was then 
expressed as mean of 4 standard abundances calculated for the four gels. 
Statistical significance of differences in spot intensity was determined by 
Student‘s t-test. Only protein spots with at least 1.2 fold-changes in volume (p< 
0.05), after normalization, were considered significantly altered. DeCyder 
software displayed in a graphic the relative abundance of each protein spot in 
CD133+ and CD133- cells, and defined a fold change expression of each 
protein, above a biological variation. An example of the DeCyder analysis is 
reported in Figure 19. 
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The image analysis revealed that 61 spots in CaCo-2 CD133+ cells and 52 in 
HCT-116 CD133+ cells were differentially expressed compared to CD133- 
cells. From two Sypro Ruby-stained preparative gels we matched and picked 
52 of 61 spots in CaCo-2 cells and 44 of 52 spots in HCT-116 cells. Excised 
spots were subjected to enzymatic digestion with trypsin and the resulting 
peptide mixtures were analyzed by mass spectrometry, MALDI MS or µLC-
MS/MS, depending on spot intensity. Figures 20A and 20B show the 
differentially expressed spots identified on preparative gels: under-expressed 
spots and over-expressed spots in CD133+ vs CD133- cells are reported in red 
and green, respectively.  
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Forty-three of the picked spots were identified in CaCo-2 cells and 38 of the 
picked spots were identified in HCT-116 cells. The differentially expressed 
proteins identified on a representative DIGE gel of CaCo-2 cells and HCT-116 
cells, respectively are shown in Figs 21A and 21B.  
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Tables 2 and 3 show the proteins identified in CaCo-2 and HCT-116 cells. For 
each protein, the spot number, gene symbol, p-value, fold change, NCBI 
accession code, protein name and theoretical pI /MW are reported. The lists 
are ranked from the highest fold change value to the lowest. This range of fold 
changes (not greater than ± 2.45) seems to be congruent with the systems 
analyzed. In fact, we studied the protein expression profiles of two 
subpopulations of cells within two ―homogeneous‖ colon cancer cell lines. 
Details of the MS analysis of the proteins identified in each cell line are 
reported in Tables 4 and 5 (Appendix, section 6). Most spots were 
unambiguously identified as single proteins: 32 in the CaCo-2  2D gel (21 over-
expressed and 11 under-expressed) and 31 in the HCT-116 2D gel (11 over-
expressed and 20 under-expressed). In total, 11 spots (2625, 2532, 2791, 
2418, 2188, 3434, 1778, 1823, 1917, 1722, 1600) in CaCo-2 gel, and 7 spots 
(spots 4928, 2989, 4000, 2941, 3934, 2053, 3112) in the HCT-116 gel were 
associated to more than one protein. In these cases, the measured fold 
change could not be directly assigned to a single protein species. Thus, these 
proteins would require further validation analysis. The HCT-116 2D preparative 
gel, contained two series of spots with the same molecular weight and different 
pI. A series of 6 spots (no 1421, 1399, 1433, 1400, 1398 and 1401) of 75 kDa 
was identified as lamin A/C, and a series of 5 spots (no 1466, 1413, 1563, 
1432 and 1445) of 70 kDa was identified as ezrin. These series of spots could 
be due to alternative post-translational modifications, namely phosphorylation 
or deamidation, or to alternative splicing protein products. Similarly, we 
attribute the increase of the pI value for Hspd1 (1388) to post translational 
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modifications, while Hsp90ab1 (2988) which appears in a spot at a lower 
molecular weight than the theoretical value, may have been extensively 
fragmented. 
Among the differentially expressed proteins of CaCo-2 CD133+ cells, we 
detected SRp20 in spot 3560 at a pI of around 6.0, while the theoretical pI 
value of SRp20 is 11.64. This discrepancy may be due to phosphorylation; in 
fact, SRp20 is known to be extensively phosphorylated on the serine residues 
in the SR domain. Furthermore, the MS/MS spectrum of the peptide [12-23] of 
SRp20 at m/z=625.03 is reported (Fig. 22). 
 
 
 
AnxA2 was detected in two contiguous spots (2747 and 2791), both of which 
were over-expressed at two slightly different molecular weights.  
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Creatine kinase B was detected in 3 over-expressed spots (2626, 2667 and 
2625) at the expected molecular weight. Hspa8 was identified in two spots 
(1823 and 1826) both over-expressed  at the expected molecular weight and 
pI. Hspa1a was detected in two spots (1906 and 1893) both down-regulated at 
two slightly different pI values, thus suggesting the possibility of post-
translational modifications of this protein. Finally, Krt8 and Jup were detected 
in spots at molecular weights lower than the theoretical value which is 
suggestive of protein degradation. In conclusion, by considering only once the 
spots containing the same protein, the total number of differentially expressed 
proteins was 49 in the case of CaCo-2 CD133+ vs CD133- cells and 36 in the 
case of HCT-116 CD133+ vs CD133- cells, while the number of differentially 
expressed proteins identified as single proteins was 32 in CaCo-2 CD133+ 
cells and 22 in HCT-116 CD133+ cells. 
There were 9 common differentially expressed proteins in CaCo-2 CD133+ 
cells (Table 2) and HCT-116 CD133+ cells (Table 3): 7 of them (Hspa1a, Krt8, 
Krt18, Hspd1, Hspa8, Hsp90ab1 and Impdh2) had a similar fold change in the 
two systems and 2 (Ugdh and Lmna) had a different trend, i.e., both are up-
regulated in CaCo -2 CD133+ cells and down-regulated in HCT-116 
CD133+cells. The fold-changes of Ugdh were very close to the threshold value 
(+1.23 in CaCo-2 and -1.22 in HCT-116), consequently, we did not investigate 
its role in CaCo-2 and HCT-116 CD133+ cells.  
In the case of Lmna this is not surprising. In fact, Willis and colleagues 
reported that the expression of A-type lamins gives rise to increased tumor 
invasiveness, thus suggesting that reduced Lmna expression could be 
associated with a more favourable prognosis for CRC patients [67]. 
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Conversely, Belt and collaborators subsequently showed that Lmna low 
expression is associated with an increased disease recurrence and, as a 
consequence, with a worse prognosis [68]. In our case we analyzed CD133+ 
and CD133- cells from two different colon cancer cell lines to look for common 
points of interest while being aware that we could also find some differences. 
Furthermore, in HCT-116, Lmna was identified in different spots, while in 
CaCo-2 Lmna was identified only in one spot. As described above, the 
presence of different pI isoforms of Lmna in HCT-116 gel could be due to post-
translational modifications and to the existence of different alternative splicing 
products of the LMNA gene. Probably the CD133+ cells of CaCo-2 and HCT-
116 express different isoforms of the same protein to fulfill different functions.  
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Table 2: Differentially expressed proteins in CaCo-2 CD133+ vs Cd133-cells 
  
Spot 
No. 
Gene 
name 
p-value 
Fold 
change  
Gene ID Protein name 
Theoretical 
pI  
Theoretical 
MW 
3560 SFRS3 0.018 1.93 gi|4506901 
Splicing factor, arginine/serine-rich 3 
(SRp20) 
11.64 19329 
2635 CSNK2A1 0.04 1.92 gi|33358120 Casein kinase II subunit alpha (CKII) 7.29 45143 
3076 GNPDA1 0.024 1.77 gi|13027378    
Glucosamine-6-phosphate 
deaminase 1  
6.42 32668 
2747 ANXA2 0.043 1.76 gi|16306978 Annexin A2 7.56 38472 
2626 CKB 0.0044 1.76 gi:49457530 Creatine kinase B-type 5.35 42513 
2625 CKB 0.0013 1.73 gi:49457530 Creatine kinase B-type 5.35 42513 
2625 MRPS27 0.0013 1.73 gi|186928850   
28S ribosomal protein S27, 
mitochondrial 
5.83 47611 
2555 METAP1 0.024 1.64 gi|577315  Methionine aminopeptidase 1 6.8 43083 
3125 LACTB2 0.0031 1.61 gi|7705793   Lactamase, beta 2 6.32 32805 
2667 CKB 0.0067 1.59 gi:49457530 Creatine kinase B-type 5.35 42513 
1701 LMNA 0.021 1.55 gi|57014047 Lamin A/C 6.44 72224 
2532 TUFM  0.033 1.53  gi|704416  Elongation factor Tu (p43) 6.31 45045 
2532 PDHA1 0.011 1.53 gi:12803199 
Pyruvate dehydrogenase E1-alpha 
precursor 
6.51 40228 
3047 ESD 0.011 1.53 gi:182265  Esterase D 6.54 31462 
2945 LDHB 0.023 1.52 gi|4557032  L-lactate dehydrogenase  5.72 36507 
2791 ANXA2 0.045 1.46 gi|16306978 Annexin A2 7.56 38472 
2791 GPD2 0.045 1.46 gi:18043793 
Glycerol-3-phosphate 
dehydrogenase 
6.51 40228 
2418 ACTR3 0.039 1.4 gi|62088286  
ARP3 actin-related protein 3 
homolog variant  
5.61 47239 
2418 DDX39B 0.039 1.4 gi|4758112 Spliceosome RNA helicase BAT1 5.44 49416 
2128 CAT 0.0055 1.39 gi|4557014 Catalase 6.95 59624 
3180 PROSC 0.009 1.37 gi:6005842 
Proline synthetase co-transcribed 
homolog 
7.09 30343 
3496 PCNP 0.043 1.36 gi|9966827 
PEST proteolytic signal-containing 
nuclear protein 
6.86 18924 
2188 TUBB2C 0.041 1.34 gi|5174735  Tubulin beta-2C chain 4.79 49831 
2188 TUBA1A 0.041 1.34 gi|37492  Tubulin alpha 5.02 50810 
3434 TPT1 0.015 1.31 gi|4507669  Fortilin (p23) 4.84 19595 
3434 JUP 0.015 1.31 gi|194373749  Catenin gamma 5.7 81744 
1823 HSPA8 0.0071 1.28 gi|5729877  
Heat shock cognate 71 kDa protein 
isoform 1  
5.37 70766 
1823 HSP90AB1 0.0071 1.28 gi|306891  
Heat shock protein 90kDa alpha 
(cytosolic) 
4.96 83133 
3352 ECHS1 0.011 1.28 gi|1922287 Enoyl-CoA hydratase 5.88 28342 
1826 HSPA8 0.013 1.25 gi|5729877  
Heat shock cognate 71 kDa protein 
isoform 1  
5.37 70766 
2179 ALDH1A1     0.05 1.25 gi|114625020 Aldehyde dehydrogenase 1A1 6.29 54730 
2178 UGDH 0.05 1.23 gi|4507813 UDP-glucose-dehydrogenase 6.73 55024 
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2409 KRT18 0.017 1.23 gi|30311   Cytokeratin 18 5.34 47926 
2742 POLDIP2 0.043 1.23 gi|7661672 
DNA polymerase delta interacting 
protein 2 (p38) 
8.8 42033 
2227 ATP5A1 0.018 1.22 gi|158259937  
ATP synthase, H+ transporting, 
mitochondrial  
8.28 55209 
1808 TCP1 0.0053 -1.2 gi|36796   t-complex polypeptide 1 5.8 60343 
2130 FARSA 0.0072 -1.21 gi|119604734  Phenylalanyl-tRNA synthetase  7.46 57432 
3053 KRT8 0.036 -1.23 gi|181573  Cytokeratin 8  5.52 53573 
2487 ALDOA 0.05 -1.25 gi|28614   Aldolase A  8.39 39288 
1917 SYNCRIP 0.024 -1.27 gi|228008398 
Heterogeneous nuclear 
ribonucleoprotein Q (hnRNP Q) 
isoform3 
7.18 62656 
1917 PCK2 0.024 -1.27 gi|2661752  
Phosphoenolpyruvate 
carboxykinase (GTP) 
8.4 47563 
1778 DDX3X 0.013 -1.27 gi|2580550 Dead box, X isoform  6.73 73625 
1778 NCL 0.013 -1.27 gi|189306 Nucleolin 4.59 76355 
2647 PSMC6 0.015 -1.33 gi|195539395 
Proteasome 26S ATPase subunit 6 
(Proteasome subunit p42) 
7.25 44041 
1722 HSPD1 0.0016 -1.35 gi|306890    Chaperonin (HSP60) 5.24 57962 
1722 PDIA4 0.0016 -1.35 gi|4758304   
Protein disulfide-isomerase A4 
precursor  
4.9 70102 
2226 IMPDH2 0.033 -1.35 gi|66933016 
Inosine monophosphate 
dehydrogenase 2  
6.44 55804 
2098 TAPBP 0.041 -1.38 gi|220702506 Tapasin 6.53 45714 
2888 HS3ST3A1 0.05 -1.4 gi|52695687 
Heparan sulfate glucosamine 3-O-
sulfotransferase 3A1 
9.54 44899 
1906 HSPA1A 0.015 -1.63 gi|6729803 Heat shock 70 kDa protein 1A/1B 5.48 69921 
1600 FLNA 0.0053 -1.86 gi|18676444  Filamin A 5.7 280607 
1600 TARS 0.0053 -1.86 gi:52632425 Threonyl-tRNA synthetase 6.2 83435 
1893 HSPA1A 0.0087 -2.19 gi|194388088 Heat shock 70 kDa protein 1A/1B 5.48 69921 
1845 ANXA6 0.0074 -2.32 gi|119582091 Annexin A6 5.46 75276 
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Table 3: Differentially expressed proteins in HCT-116 CD133+ vs Cd133- cells   
Spot 
No. 
Gene name p-value 
Fold 
Change 
Gene ID Protein name 
Theoretical 
pI  
Theoretical 
MW 
4928 PRDX1 0.035 2.45 gi|4505591  Peroxiredoxin-1  8.27 22110 
4928 PEBP1 0.035 2.45 gi|913159 Neuropolypeptide h3 7.42 21027 
2988 HSP90AB1 0.014 2.13 gi|306891  
Heat shock protein 90kDa alpha 
(cytosolic) 
4.96 83133 
3826 HSPB1 0.0073 1.92 gi|662841   Heat shock protein 27  (Hsp27) 5.98 22782 
4323 CDC42 0.001 1.83 gi|4757952  Cell division control protein 42 
homolog isoform 1 
6.16 20933 
4018 PRTFDC1 0.015 1.68 gi|9910262  Phosphoribosyltransferase 
domain-containing protein 1  
5.77 25542 
2989 ANXA1 0.013 1.44 gi|4502101  Annexin A1 
6.64 38583 
2989 HNRNPH3 0.013 1.44 gi 14141157 
Heterogeneous nuclear 
ribonucleoprotein H3 isoform a 6.8 36925 
4000 PRDX4 0.034 1.41 gi|5453549 Peroxiredoxin-4 5.54 26572 
4000 PRDX6 0.034 1.41 gi|3318841 Peroxiredoxin 6 6.02 24903 
2941 CPOX 0.02 1.37 gi|840693  Coproporphyrinogen oxidase  6.32 39248 
2941 HNRNPC 0.02 1.37 gi|306875 
Heterogeneous nuclear 
ribonucleoprotein C (C1/C2) 
5.01 33538 
3934 ACTB 0.025 1.33 gi|15277503 Actin beta 5.29 41736 
3934 ENO 0.025 1.33 gi|2661039 Enolase 6.5 36628 
2903 TALDO1 0.0015 1.3 gi|5803187  Transaldolase 6.36 37540 
3578 CLIC1 0.031 1.28  gi|895845  
Chloride intracellular channel 
protein 1  
5.09 26791 
1627 HSPA8 0.01 1.26 gi|5729877  
Heat shock cognate 71 kDa 
protein isoform 1  
5.37 70766 
2684 SEPT2 (DIFF6) 0.048 1.23 gi|4758158   Septin 2  6.15 41487 
1692 SDHA 0.04 1.22 gi|119571367  
Succinate dehydrogenase 
complex, subunit A, flavoprotein 
(Fp) 6.25 68012 
2351 KRT18 0.018 1.22 gi|30311   Keratin 18  
5.34 47926 
2761 
ALDR1 0.016 1.21 gi|5174391  Alcohol dehydrogenase [NADP+] 6.35 36441 
1759 STIP1 0.031 -1.21 gi|114638255 
Hsp70/hsp90 organizing 
protein(HOP) 
6.4 62639 
2053 PHGDH 0.0067 -1.21 gi|23308577 Phosphoglycerate dehydrogenase 
6.31 56519 
2053 IMPDH2 0.0067 -1.21 gi:66933016 
Inosine monophosphate 
dehydrogenase 2  6.44 55804 
2319 FH 0.0021 -1.21 gi|19743875 Fumarate hydratase precursor  7.0 50081 
1388 HSPD1 0.024 -1.22 gi|306890    Chaperonin (HSP60) 5.24 57962 
2063 UGDH 0.043 -1.22 gi|4507813 UDP-glucose dehydrogenase 6.73 55024 
1421 LMNA - LMN1 0.013 -1.24 gi|57014047 Lamin A/C 6.44 72224 
2215 KRT8 0.049 -1.33 gi|119617057 Keratin8  5.52 53573 
1466 EZR 0.036 -1.36 gi|46249758 Ezrin 5.95 69281 
1207 KHSRP 0.0037 -1.37 gi|2055427  
KSRP /KH type-splicing regulatory 
protein (p75) 6.85 73115 
1401 LMNA-LMN1 0.0099 -1.4 gi|27436946   Lamin-A/C  6.44 72224 
3206 MDH1 0.02 -1.4 gi|5174539 Cytosolic malate dehydrogenase  6.89 36294 
1413 EZR 0.0036 -1.43 gi|46249758 Ezrin 5.95 69281 
3112 ANXA3 0.017 -1.44 gi|4826643  Annexin A3 5.63 36244 
3112 PPA1 0.017 -1.44 gi|11056044   Inorganic pyrophosphatase 5.54 32660 
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1563 EZR 0.027 -1.45  Ezrin 5.95 69281 
1432 EZR 0.012 -1.47 gi|46249758 Ezrin 5.95 69281 
1399 LMNA - LMN1 0.026 -1.5 gi|57014047 Lamin A/C 6.44 72224 
1073 EEF2 0.042 -1.51 gi|4503483  Elongation factor 2 6.42 95206 
1673 HSPA1A 0.0096 -1.53 gi|167466173 Heat shock protein 70 (Hsp70) 5.48 69921 
1433 LMNA - LMN1 0.033 -1.62 gi|57014047 Lamin A/C 6.44 72224 
1400 LMNA - LMN1 0.0098 -1.68 gi|57014047 Lamin A/C 6.44 72224 
1445 EZR 0.018 -1.78 gi|46249758 Ezrin 5.95 69281 
1398 LMNA - LMN1 0.045 -1.86 gi|57014047 Lamin A/C 6.44 72224 
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3.4 Validation of differentially expressed proteins 
We searched the literature to try to identify colon CSC markers among our 
differentially expressed proteins and to identify cellular processes deregulated 
in CD133+ cells. We included in the group of proteins selected for validation by 
western blotting, a few species closely related to our protein set. Western blot 
analyses were performed on freshly prepared protein extracts of CaCo-2 and 
HCT-116 CD133+ and CD133- cells. GAPDH was used as loading control of 
each sample. Semi-quantitative analyses of protein expression were performed 
for each validated protein. We analyzed the expression of the following 
proteins in the CaCo-2 CD133+ vs CD133- cells: SRp20, γ-catenin, β-catenin, 
CKII, lamin A/C, AnxA1 and AnxA2 (Fig. 23).  
 
 
The western blot experiments confirmed the up-regulation of SRp20, catenin γ, 
CKII, lamin A/C and AnxA2 in CD133+ cells. In addition, β-catenin and AnxA1 
were differentially expressed in the system, all of them being up-regulated. 
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Hsp27, cytokeratin 8, lamin A/C, AnxA1, AnxA2, SRp20, CKII, β-catenin and γ-
catenin were chosen for western blotting and densitometric analysis of HCT-
116 CD133+ vs CD133- cells (Fig. 24). The analysis confirmed the up-
regulation of Hsp27 and AnxA1 and the down-regulation of KRT8 and lamin 
A/C in CD133+ cells. Interestingly, as demonstrated in the CaCo-2 system, 
SRp20 and β-catenin were up-regulated in the HCT-116 CD133+ cells, 
whereas no relevant differences were detected as regards CKII, γ-catenin and 
AnxA2. 
 
 
 
Finally, to determine whether SRp20, CKII, γ-catenin and β-catenin belong to 
distinctive molecular pathways of cancer stem-like cells (CSLCs), the level of 
expression of these proteins was investigated in CD133+ vs CD133- cells 
isolated from another colorectal carcinoma cell line, namely HT-29 (Fig. 25).  
 67 
 
 
 
The analysis confirmed the up-regulation of SRp20 and CKII in CD133+ cells, 
whereas no significant change was observed for γ-catenin and β-catenin. 
In conclusion, SRp20 was over-expressed in CD133+ vs CD133-cells isolated 
from all three CRC cell lines: CaCo-2, HCT-116 and HT-29. This 
overexpression amounts to about two-fold in all the three CRC cell lines. 
 
3.4 Biological network analysis 
To identify processes connected with CD133+ cells, we analyzed separately 
the groups of differentially expressed proteins listed in Table 2 and Table 3 for 
each cell line using the IPA software. The system created three high-score 
multidirectional interaction networks for CaCo-2 cells. One was related to 
―cellular movement‖ (score=51), one to ―energy production, small molecule 
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biochemistry‖ (score=33) and one to ―cell signaling‖ (score= 27). To have a 
complete graphical vision of all the proteins identified in our analysis, we 
merged the three CaCo-2 networks into a single network (Fig. 26). The 
network revealed several nodes of proteins, genes and/or molecules (NFkB, 
Caspase, MCC) directly or indirectly correlated with the proteins we identified. 
In the case of HCT-116, the IPA output generated three networks: ―cellular 
movement‖ (score= 44), ―energy production, small molecule biochemistry‖ 
(score= 24) and ―cellular growth and proliferation‖ (score=9). Figure 27 shows 
the merged image of all three HCT-116 networks.  
We also performed an ontological analysis on our data set and, in agreement 
with IPA output, the ―cellular catabolic process, energy production‖ GO term 
was statistically significant for both cell lines (GO: 0044265, CaCo-2 p-value 
3.0E-05; HCT-116, GO:0009109 p-value 7.5E-04). 
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3.5 Effects of Wnt/β catenin pathway activation on SRp20 expression 
There is evidence that SRp20 expression can be regulated by the Wnt/β-
catenin pathway [69]. To evaluate whether this occurs in our system, we 
stimulated pathway activation by adding Wnt ligand to the CaCo-2 culture 
medium and we estimated SRp20, β-catenin and CKII expression by western 
blotting (Fig. 28). Cells were withdrawn at 48 h and 72 h. Total β-catenin was 
increased in the presence of Wnt after 48 h and 72 h, which confirms activation 
of the Wnt pathway. The expression profile of SRp20 and CKII was the same 
as that of β-catenin, i.e., it increased 48 h and 72 h after treatment with Wnt 
ligand. 
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3.6 Effects of silencing of SRp20  
We next investigated the role of SRp20 on cell proliferation and found that 
CaCo-2 cells proliferation decreased after SRp20 expression was knocked 
down by a siRNA targeting SRp20 mRNA (Fig. 29 A). This result indicates that 
increased SRp20 expression is necessary for the indefinite growth of cancer 
cells. We also found that SRp20 was up-regulated in CD133+ cells, thus 
indicating that SRp20 could play a crucial role in the higher tumorigenicity of 
this subpopulation of cells. 
We also evaluated if SRp20 silencing affected the expression of MCC, β-
catenin and γ-catenin. Interestingly, immunoblotting showed that SRp20 
silencing increased MCC expression and decreased the expression of β-
catenin and γ-catenin (Fig. 29 B). 
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4. DISCUSSION 
A tumor is constituted by heterogeneous cells. The long-held view of 
tumor development, according to the stochastic model, is that each 
tumor cell is equally capable of initiating neoplastic growth. This theory 
has recently been challenged by the CSC theory, which suggests that 
only a small proportion of cells within a tumor possess cancer-initiating 
potential and that these so-called CSCs sustain tumor growth and may 
be associated with metastasis, treatment resistance and recurrence 
[70]. During this PhD program, a differential proteomic analysis on two 
human colon carcinoma cell lines, CaCo-2 and HCT-116, was 
conducted. Both cell lines were sorted according to the expression of 
the stemness marker CD133 in the attempt to identify proteins and/or 
cellular processes distinctive of colon CSCs. CD133+ cells were 
assumed to be CSLCs. By counting only once the protein spots that 
contained the same protein, the comparative experimental approach 
revealed 49 differentially expressed proteins (31 up-regulated and 18 
down-regulated) in CaCo-2 CSLCs and 36 differentially expressed 
proteins (21 up-regulated and 15 down-regulated) in HCT-116 CSLCs. 
Some of the identified species were further validated in a third colon 
carcinoma cell line, namely HT-29. The results of this PhD thesis show 
that two relevant interconnected processes are activated in the CSLCs 
subpopulation: energy metabolism and the Wnt pathway. 
Both the ontological and the IPA analyses showed that a group of 
proteins identified are involved in cellular energy metabolism. Among 
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the proteins differentially expressed in CaCo-2 CD133+ cells (Table 2), 
glucosamine-6-phosphate isomerase 1 (Gnpda1), lactate 
dehydrogenase (Ldhb), enoyl-CoA hydratase (Echs1), the well-
established CSC marker aldehyde dehydrogenase 1A1 (Aldh1a1) [71-
73]. ATP synthase subunit alpha (Atp5a1), aldolase A (Aldoa) and 
inosine monophosphate dehydrogenase 2 (Impdh2) are involved in 
energy metabolism. Collectively, these proteins account for 22% (7/32) 
of the singly identified proteins. A similar result was obtained for proteins 
differentially expressed in HCT-116 CD133+ cells (Table 3). In fact the 
species involved in energy metabolism represent 23% (5/22) of the 
singly identified proteins; these are alcohol dehydrogenase [NADP+] 
(Akr1a1), the tumor suppressor fumarate hydratase (Fh), transaldolase I 
(Taldo1), succinate dehydrogenase (Sdha) and cytosolic malate 
dehydrogenase (Mdh1). Metabolic reprogramming, called the ―Warburg 
effect‖ [74], is a hallmark of cancer cells that undergo ―aerobic 
glycolysis‖ thereby giving rise to enhanced lactate production [75]. The 
expression of most of the identified proteins suggests that metabolic 
reprogramming is activated in CaCo-2 and HCT-116 CSLCs. 
Furthermore, examination of the CaCo-2 IPA network (Fig. 26) shows 
that several differentially expressed proteins are connected with protein 
MCC (mutated in colorectal cancer), a negative regulator of Wnt/-
catenin signal transduction [76]; in this study there is evidence of Wnt/-
catenin signaling activation. 
The Wnt signaling cascade is conserved throughout the animal kingdom 
and, depending on the context, it plays various roles in stem cell 
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maintenance, cell proliferation, differentiation, and apoptosis [77]. Given 
its fundamental role in homeostasis in human adult tissue, it is not 
surprising that deregulation of the Wnt pathway is associated with 
various pathologic states, including various types of cancer [78, 79]. The 
differential proteomic study performed shows that some proteins 
identified are closely related to the signal transduction pathway of the 
Wnt protoncogene. SRp20 and CKII were up-regulated in CaCo-2 
CD133+ cells, whereas KSRP/KH type-splicing regulatory protein 
(Khsrp) was down-regulated in HCT-116 CD133+ cells. SRp20 is a 
serine/arginine-rich splicing factor recently characterized as a novel 
target of β-catenin/TCF4 signalling through the Wnt canonical pathway 
[69]. CKII, when over-expressed, induces neoplastic growth, thereby 
acting as an oncogene [80]. CKII was recently implicated in the 
regulation of β-catenin stability [81]. In fact, it positively regulates β-
catenin phosphorylation at the level of Thr393, and thus inhibits 
proteasome-mediated degradation of β-catenin [81]. Its kinase activity 
promotes survival by increasing residual gene expression via β-catenin-
TCF/LEF-mediated transcription [82]. Khsrp is a KH-type splicing 
regulatory protein able to negatively regulate Wnt/ β-catenin signaling at 
the level of post-transcriptional β-catenin-mRNA stability [83]. Its down-
regulation indicates the activation of specific molecular mechanisms 
aimed at stabilization of β-catenin mRNA. β-catenin was up-regulated in 
CaCo-2 and HCT-116 CD133+ cells (Figs. 23 and 24). These findings 
suggested that the Wnt pathway was activated in the CSLCs. The 
western blot analyses performed in the Caco-2, HCT-116 and HT-29 cell 
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lines sorted by CD133 confirmed this hypothesis and revealed the up-
regulation of the splicing factor SRp20 in all the three CSLC systems 
under investigation (Figs. 23, 24 and 25). Moreover, by stimulating 
CaCo-2 cells with Wnt ligand an activation of the Wnt pathway was 
reproduced and, as a consequence, an up-regulation of CKII and SRp20 
was found (Fig. 28). 
SRp20 is the smallest member of the SR protein family [84]. It 
modulates alternative splicing of CD44 cell adhesion protein in two 
colorectal cell lines (SW480, DLD-1) [69]. Its knockdown causes 
apoptosis in ovarian cancer cells whereas its expression is associated 
with malignancy of epithelial ovarian cancer [85]. SRp20 is over-
expressed in many cancer types and its increase is critical for cell 
proliferation, tumor induction and maintenance [86]. 
When SRp20 was silenced in the CaCo-2 cell line, cell proliferation 
slowed down (Fig. 29A), which suggests that SRp20 plays a role in the 
tumorigenicity of CSLCs. In addition, the results of this thesis show that 
SRp20 exerts a powerful effect on MCC protein expression (Fig. 29B). 
Fukuyama and colleagues reported that MCC expression is dramatically 
decreased in many CRC cell lines; importantly, they found that MCC 
interacts with -catenin and finally that re-expression of MCC in CRC 
cells inhibits Wnt signaling [76]. The data of this thesis demonstrate that 
when SRp20 is silenced, MCC expression is increased, while -catenin 
and -catenin expression is decreased (Fig. 29B), thereby suggesting a 
slowing-down of the Wnt pathway. These data are in accordance with 
the hypothesis that SRp20 expression is closely correlated with Wnt 
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pathway activation and also suggest that SRp20 could act as a regulator 
of the pathway by modulating MCC expression. 
In this study, a positive correlation among CD133 expression, Wnt 
pathway activation and increased SRp20 expression was found. Based 
on these findings it is possible to propose a model of putative sequential 
molecular events that characterize colon CSLCs in which the β-
catenin/TCF4 pathway would stimulate gene transcription and thus the 
production of transcript variants through alternative splicing mediated by 
SRp20.  
In summary, the results of this PhD thesis showed i) activation of 
metabolic reprogramming in CSLCs that is potentially connected to Wnt 
pathway activation ii) over-expression of SRp20 in the CSLCs of three 
different colon cancer cell lines; iii) a direct correlation between Wnt 
pathway activation and SRp20 expression; iv) the possibility that SRp20 
plays a role in the tumorigenicity of colon CSLCs and v) the possibility 
that SRp20 modulates the Wnt pathway, where also the expression of 
MCC is involved. 
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                6. APPENDIX I 
Table 4: MS details of CaCo-2 identified proteins     
Spot 
No. 
Id 
Method 
Protein name 
Mascot 
Protein 
Score 
Sequence 
coverage 
(%) 
Identified peptide sequence 
Ion 
Score 
(MS/MS) 
Precursor 
mass 
(m/z) 
Mass 
error 
(ppm) 
3560 MSMS 
Splicing factor, 
arginine/serine-rich 3 
(SRp20) 
141 10 VYVGNLGNNGNK 74 625,03 240 
     VYVGNLGNNGNKTELER 67 626,70 79 
         
2635 MS 
Casein Kinase II 
(CKII) 
159 51 VYTDVNTHRPR  1357,55 110 
     EYWDYESHVVEWGNQDDYQLVR  2830,00 84 
     GKYSEVFEAINITNNEK  1955,75 112 
     GGPNIITLADIVKDPVSR  1864,80 134 
     TPALVFEHVNNTDFK  1731,68 109 
     QLYQTLTDYDIR  1528,56 130 
     FYMYEILK  1122,44 98 
     LIDWGLAEFYHPGQEYNVR  2306,85 117 
     KEPFFHGHDNYDQLVR  2001,72 119 
     EPFFHGHDNYDQLVR  1873,64 117 
     VLGTEDLYDYIDKYNIELDPR  2544,43 71 
     FNDILGR  834,36 108 
     FVHSENQHLVSPEALDFLDK  2324,87 120 
     YDHQSR  805,28 99 
     EAMEHPYFYTVVK  1629,59 104 
         
3076 MSMS 
Glucosamine-6-
phosphate deaminase 
1  
411 30 LVDPLYSIK 47 524,20 210 
     IIQFNPGPEK 49 571,68 235 
     EVMILITGAHK 44 614,20 225 
     TLAMDTILANAR 74 653,18 253 
     TFNMDEYVGLPR 68 729,18 219 
     TVFVCDEDATLELK 72 820,17 280 
     VPTMALTVGVGTVMDAR 57 875,24 228 
         
2747 MSMS Annexin A2 365 16 TPAQYDASELK 58 612,12 65 
     TNQELQEINR 67 623,02 233 
     GLGTDEDSLIETICSR 48 889,80 90 
     SLYYYIQQDTKGDYQK 63 672,10 54 
     RAEDGSVIDYELIDQDAR 76 689,20 184 
     AYTNFDAERDALNIETAIK 53 719,31 190 
         
2626 MSMS 
Creatine Kinase B 
type 
590 33 LLIEMEQR+ Oxidation (M) 44 524,29 28 
     DLFDPIIEDR 46 616,90 146 
     VLTPELYAELR 45 652,51 222 
     LAVEALSSLDGDLAGR. 99 793,90 19 
     LEQGQAIDDLMPAQK 69 836,91 6 
     
LGFSEVELVQMVVDGVK.L + Oxidation 
(M) 
85 933,14 160 
     GTGGVDTAAVGGVFDVSNADR 55 655,80 229 
     AIEKLAVEALSSLDGDLAGR 89 676,82 172 
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     TDLNPDNLQGGDDLDPNYVLSSR 58 840,10 47 
         
2625 MSMS 
Creatine Kinase B 
type 
360 22 VLTPELYAELR 48 625,50 153 
     LAVEALSSLDGDLAGR. 102 794,04 145 
     LEQGQAIDDLMPAQK + Oxidation (M) 56 558,41 215 
     
LGFSEVELVQMVVDGVK + Oxidation 
(M)  
58 933,09 107 
     GTGGVDTAAVGGVFDVSNADR 51 655,77 183 
     RGTGGVDTAAVGGVFDVSNADR 45 707,62 89 
         
 MSMS 
28S ribosomal protein 
S27, mitochondrial 
219 11 EALDVLGAVLK 50 564,44 186 
     LVEQLDIEETEQSK 123 831,04 150 
     ALTSADGASEEQSQNDEDNQGSEK 46 837,20 159 
         
2555 MSMS 
Methionine 
aminopeptidase 1 
93 5 YRELGNIIQK 43 412,13 40 
     NGYHGDLNETR 50 771,80 18 
         
3125 MSMS Lactamase, beta 2 139 9 SINNDTTYCIK 61 665,10 195 
     EEIIGNGEQQYVYLK 78 892,16 300 
         
2667 MSMS 
Creatine Kinase B 
type 
323  LLIEMEQR 49 524,32 76 
     VLTPELYAELR 44 652,51 222 
     LAVEALSSLDGDLAGR. 93 794,06 170 
     LEQGQAIDDLMPAQK + Oxidation (M) 74 837,06 173 
     GTGGVDTAAVGGVFDVSNADR 63 983,05 81 
         
1701 MS Lamin A/C 162 33 LQEKEDLQELNDR  1629,81 0 
     SLETENAGLR  1089,52 27 
     ITESEEVVSR  1148,56 17 
     AAYEAELGDAR  1165,53 16 
     EGDLIAAQAR  1043,37 95 
     TLEGELHDLR  1182,62 8 
     QLQDEMLRR  1187,53 32 
     NIYSEELR  1023,44 68 
     LADALQELR  1028,49 77 
     NSNLVGAAHEELQQSR  1752,81 28 
     IRIDSLSAQLSQLQK  1699,91 35 
     LALDMEIHAYR.  1347,62 37 
     LSPSPTSQR  972,46 51 
     SSFSQHAR  919,39 54 
     VAVEEVDEEGKFVR  1605,77 25 
     ASASGSGAQVGGPISSGSSASSVTVTR  2365,1 25 
     SVGGSGGGSFGDNLVTR  1566,75 0 
     TQSPQNCSIM  1165,5 0 
         
2532 MSMS Elongation factor Tu 577 26 GTVVTGTLER 53 516,71 249 
     VEAQVYILSK 64 575,21 208 
     YEEIDNAPEER 58 682,66 252 
     QIGVEHVVVYVNH 65 733,83 238 
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     KYEEIDNAPEER 69 746,65 229 
     LLDAVDTYIPVPAR 51 771,90 146 
     GEETPVIVGSALCALEGR 50 929,26 234 
     TIGTGLVTNTLAMTEEEK 65 962,22 275 
     ADAVQDSEMVELVELEIR 102 1031,27 225 
         
 MSMS 
Pyruvate 
dehydrogenase E1-
alpha precursor 
240 11 EILAELTGR 56 501,15 269 
     YGMGTSVER 60 508,08 295 
     VDGMDILCVR 50 597,28 244 
     LEEGPPVTTVLTR 74 706,20 276 
         
3047 MSMS  Esterase D 169 29 DDQFLLDGQLLPDNFIAACT EK 68 842,15 126 
     GEDESWDFGTGAGFYVDATE DPWK 48 893,97 280 
     
SYPGSQLDILIDQGKDDQFL 
LDGQLLPDNFIAACTEK 
53 1380,20 240 
         
2945 MSMS 
L-lactate 
dehydrogenase B  
245 13 IVVVTAGVR 62 457,12 128 
     GLTSVINQK  51 480,20 104 
     MVVESAYEVIK 42 642,14 230 
     IVADKDYSVTANSK 90 755,63 280 
         
2791 MSMS Annexin A2 722 48 AYTNFDAER 43 543,58 300 
     DALNIETAIK 51 544,17 248 
     TPAQIDASELK 61 611,63 278 
     DIISDTSGDFR 56 613,27 16 
     TNQELQEINR 67 622,80 24 
     SYSPYDMLESIR 49 738,75 218 
     GVDEVTIVNILTNR 82 711,82 280 
     GLGTDEDSLIETICSR 63 889,81 165 
     TDLEKDIISDTSGDFR 43 604,77 220 
     AEDGSVIDYELIDQDAR 78 954,64 300 
     RAEDGSVIDYELIDQDAR 75 688,80 290 
     AYTNFDAERDALNIETAIK 54 718,89 280 
         
  
Glyceraldeide-3-
phosphate 
dehydrogenase 
121 5 VPTANVSVVDLTCR 59 765,70 260 
     VIHDNFGIVEGLMTTVHAITATQK 62 870,90 300 
         
2418 MSMS 
ARP3 actin-related 
protein 3 homolog 
variant  
328 18 LSEELSGGR 59 474,37 260 
     FMEQVIFK.Y + Oxidation (M) 48 502,36 236 
     LKLSEELSGGR 49 594,95 193 
     QYTGINAISKK 48 603,46 215 
     NIVLSGGSTMFR.D + Oxidation (M) 68 649,47 215 
     DREVGIPPEQSLETAK 56 590,43 209 
         
 MSMS 
Spliceosome RNA 
helicase BAT1 
125 6 ILVATNLFGR 54 552,30 45 
     GLAITFVSDENDAK 71 740,48 148 
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2128 MS Catalase 135 30 ADVLTTGAGNPVGDKLNVITVGPR  2363,99 126 
     GAGAFGYFEVTHDITK  1712,82 111 
     VFEHIGKK  957,54 104 
     KTPIAVR  784,50 89 
     TPIAVR  656,40 91 
     FSTVAGESGSADTVRDPR  1851,67 113 
     NLSVEDAAR  974,39 102 
     LSQEDPDYGIR  1292,47 108 
     LFAYPDTHR  1119,43 116 
     LGPNYLHIPVNCPYR  1812,74 99 
     VANYQR  750,32 120 
     FNTANDDNVTQVR  1493,54 107 
     AFYVNVLNEEQR  1481,57 114 
     NAIHTFVQSGSHLAAR  1708,70 111 
         
3180 MSMS 
Proline synthetase 
co-transcribed 
homolog 
293 32 DLPAIQPR 46 455,17 110 
     VMVQINTSGEESK 61 719,14 277 
     TFGENYVQELLEK 82 785,16 286 
     HGLPPSETIAIVEHINAK 46 642,53 233 
     LMAVPNLFMLETVDSVK 58 969,76 247 
         
3496 MSMS 
PEST proteolytic 
signal-containing 
nuclear protein 
138 15 DTPTSAGPNSFNK 43 668,58 172 
     SAEEEAADLPTKPTK 95 529,78 239 
         
2188 MSMS Tubulin beta-2C chain 218 14 LAVNMVPFPR + Oxidation (M) 68 580,45 224 
     EVDEQMLNVQNK + Oxidation (M) 58 731,85 62 
     AVLVDLEPGTMDSVR + Oxidation (M) 44 809,54 160 
     
MSMKEVDEQMLNVQNK.N + 3 
Oxidation (M) 
48 658,03 96 
         
 MSMS Alpha-tubulin 176 10 DVNAAIATIK 61 508,40 197 
     AVFVDLEPTVIDEVR 45 851,55 111 
     TIGGGDDSFNTFFSETGAGK 70 1004,56 109 
         
3434 MSMS Catenin gamma 164 5 LLNDEDPVVVTK 48 671,24 186 
     TMQNTSDLDTAR  61 684,70 143 
     ALMGSPQLVAAVVR 55 714,35 70 
         
  Fortilin (p23) 87 16 VKPFMTGAAEQIK 44 479,73 248 
     EDGVTPYMIFFK 43 731,66 260 
         
1823 MSMS 
Heat shock cognate 
71 kDa protein 
isoform 1  
265 8 FEELNADLFR 60 627,41 159 
     TTPSYVAFTDTER 90 744,49 181 
     SFYPEEVSSMVLTK  Oxidation (M) 50 817,01 141 
     
NQVAMNPTNTVFDAK.R + Oxidation 
(M) 
65 833,48 96 
         
 MSMS 
Heat shock protein 
90kDa alpha 
(cytosolic) 
138 3 YIDQEELNK 56 576,39 182 
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     GVVDSEDLPLNISR. 82 757,50 138 
         
         
         
3352 MSMS 
Enoyl-CoA hydratase, 
mitochondrial 
302 27 AFAAGADIK 44 432,51 34 
     GKNNTVGLIQLNRPK 43 551,78 248 
     ESVNAAFEMTLTEGSK 68 865,80 293 
     TFEEDPAVGAIVLTGGDK 88 916,37 291 
     AQFAQPEILIGTIPGAGGTQ R 59 1063,44 227 
         
1826 MSMS 
Heat shock cognate 
71 kDa protein 
isoform 1  
259 8 FEELNADLFR 55 627,39 159 
     TTPSYVAFTDTER 80 744,48 181 
     SFYPEEVSSMVLTK  Oxidation (M) 70 817,01 140 
     
NQVAMNPTNTVFDAK.R + Oxidation 
(M) 
54 833,46 95 
         
2179 MS 
Aldheyde 
dehydrogenase 1A1 
134 37 LADLIERDR  1100,66 45 
     TIPIDGNFFTYTR  1544,85 51 
     LIKEAAGK  829,52 12 
     RVTLELGGK  972,63 51 
     IFVEESIYDEFVR  1645,89 48 
     IFVEESIYDEFVRR  1802,04 72 
     RSVER  646,40 62 
     YILGNPLTPGVTQGPQIDKEQYDK  2674,50 48 
     ILDLIESGKK  1115,73 53 
     GYFVQPTVFSNVTDEMR  2006,09 79 
     IAKEEIFGPVQQIMK  1747,02 40 
     SLDDVIKR  945,58 42 
     ANNTFYGLSAGVFTK  1589,87 44 
     ELGEYGFHEYTEVK  1700,88 58 
         
2178 MS 
UDP glucose 
dehydrogenase 
100 26 VTVVDVNESR  1117,69 98 
     YIEACAR  882,50 102 
     VLIGGDETPEGQR  1370,82 94 
     LAANAFLAQR  1074,71 93 
     YWQQVIDMNDYQR  1774,95 90 
     IIDSLFNTVTDKK  1493,98 107 
     YLMDEGAHLHIYDPK  1818,02 93 
     EQIVVDLSHPGVSEDDQVSR  2209,29 99 
     MLKPAFIFDGR  1310,83 106 
     RIPYAPSGEIPK  1327,85 82 
     FSLQDPPNK  1045,66 120 
         
2409 MSMS Cytokeratin 18 357 16 VIDDTNITR 65 523,79 28 
     IVLQIDNAR 58 521,38 144 
     IIEDLRAQIFANTVDNAR 54 687,18 208 
     TVQSLEIDLDSMR + Oxidation (M) 60 761,94 85 
     QAQEYEALLNIK 72 710,58 282 
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     QSVENDIHGLR + Pyro-glu (N-term Q) 48 625,84 48 
         
2742 MS 
DNA polymerase 
delta interacting 
protein 2 
217 46 GVVLFPWQAR  1172,73 59 
     LYDRDVASAAPEK  1434,83 76 
     GKTHTYYQVLIDAR  1664,98 60 
     THTYYQVLIDAR  1479,85 60 
     DCPHISQR  1012,54 79 
     SQTEAVTFLANHDDSR  1790,97 78 
     FLLYDQTK  1027,62 68 
     APPFVAR  757,49 66 
     NHPWLELSDVHR  1502,85 66 
     ETTENIR  862,50 81 
     VTVIPFYMGMR  1345,78 89 
     EAQNSHVYWWR  1475,80 81 
     LENLDSDVVQLR  1400,84 71 
     ERHWR  783,46 76 
     IFSLSGTLETVR  1322,82 68 
     GRGVVGR  700,43 19 
     GVVGREPVLSK  1140,75 70 
     FERPDGSHFDVR  1461,79 68 
         
2227 MSMS 
ATP synthase, H+ 
transporting, 
mitochondrial  
177 8 VVDALGNAIDGK 82 586.61  85 
     NVQAEEMVEFSSGLK 50 843,04 136 
     GMSLNLEPDNVGVVVFGNDK 45 707,44 280 
         
1808 MSMS 
t-complex 
polypeptide 1 
90 4 EQLAIAEFAR 45 574,42 191 
     FATEAAITILR 45 603,47 199 
         
2130 MS Phenylalanyl-tRNA 
synthetase  
84 21 STKHWELTAEGEEIAR  1856,67 129 
     HWELTAEGEEIAR  1540,61 84 
     EGSHEAR  785,30 63 
     SIPPEGLAQSELMR  1527,67 72 
     LQLVR  628,37 63 
     LGEKER  731,35 68 
     THSQGGYGSQGYK  1369,50 80 
     THTTSASAR  931,38 85 
     KPFTPVK  816,43 85 
     YFSIDR  800,34 62 
     YGINNIR  849,39 82 
     LDAEPRPPPTQEAA  1491,61 87 
         
3053 MSMS Cytokeratin 8  179 9 SLDMDSIIAEVK.A + Oxidation (M) 60 668,91 112 
     TEMENEFVLIK.K + Oxidation (M) 59 684,98 175 
     R.LEGLTDEINFLR.Q 60 710,51 183 
         
2487 MSMS Aldolase A  84 14 GVVPLAGTNGETTTQGLDGL SER                                        42 1137,08 127 
     VDKGVVPLAGTNGETTTQGL DGLSER 42 872,42 220 
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1917 MSMS 
Heterogeneous 
nuclear 
ribonucleoprotein Q 
(hnRNP Q) isoform3 
229 9 LMMDPLTGLNR + 2 Oxidation (M) 49 646,94 185 
     TGYTLDVTTGQR 54 656,48 229 
     NLANTVTEEILEK 82 737,49 129 
     DLFEDELVPLFEK 44 797,52 144 
         
  
Phosphoenolpyruvate 
carboxykinase (GTP) 
124  EVLAELEALER 63 636,41 102 
     LGTPVLQALGDGDFVK 61 815,52 92 
         
1778 MSMS Dead box, X isoform  308 14 DLLDLLVEAK 50 564,90 124 
     SPILVATAVAAR 60 584,92 111 
     DSLTLVFVETK. 48 626,40 88 
     ELAVQIYEEAR 54 660,93 128 
     MLDMGFEPQIR.R + 2 Oxidation (M) 48 684,97 219 
     VGNLGLATSFFNER 48 763,01 151 
         
  Nucleolin 154 6 NDLAVVDVR 55 500,87 190 
     GFGFVDFNSEEDAK 45 781,46 147 
     GLSEDTTEETLKESFDGSVR 54 734,11 131 
         
         
2647 MS 
Proteasome 26S 
ATPase subunit 6 
139 38 DKALQDYR  1008,46 49 
     LLEHKEIDGR  1209,61 41 
     ELREQLK  915,48 43 
     YVVGCR  753,35 26 
     LKPGTR  671,40 29 
     VALDMTTLTIMR  1396,65 71 
     GCLLYGPPGTGK  1219,57 32 
     VVSSSIVDKYIGESAR  1709,81 58 
     EMFNYAR  946,37 42 
     FSEGTSADREIQR  1495,65 40 
     KIHIDLPNEQAR  1433,71 55 
     IHIDLPNEQAR  1305,65 45 
     HGEIDYEAIVK  1273,59 39 
     LSDGFNGADLR  1164,51 42 
     NVCTEAGMFAIR  1384,59 28 
     ADHDFVVQEDFMK  1596,63 44 
         
1722 MSMS Chaperonin (HSP60) 206 11 AAVEEGIVLGGGCALLR 92 843,00 53 
     ALMLQGVDLLADAVAVTMGPK 57 710,47 122 
     TALLDAAGVASLLTTAEVVVTEIPKEEK 57 957,03 170 
         
  
Protein disulfide-
isomerase A4 
precursor  
119  IDATSASVLASR 76 595,92 168 
     MDATANDVPSDR + Oxidation (M) 43 654,32 61 
         
2226 MS 
Inosine 
monophosphate 
dehydrogenase 2 
227 39 KYEQGFITDPVVLSPK  1820,97 5 
     VRDVFEAK  963,53 0 
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     HGFCGIPITDTGR  1430,7 13 
     EANEILQR  972,5 0 
     GKLPIVNEDDELVAIIAR  1965,15 25 
     LPIVNEDDELVAIIAR  1779,98 7 
     NRDYPLASK  1063,64 84 
     DKYPNLQVIGGNVVTAAQAK  2086,18 20 
     NLIDAGVDALR  1156,63 0 
     VSEYAR  724,37 13 
     RFGVPVIADGGIQNVGHIAK  2048,19 22 
     FGVPVIADGGIQNVGHIAK  1892,03 4 
     YRGMGSLDAMDK  1376,62 14 
     HLSSQNRYFSEADK  1681,85 35 
     YFSEADKIK  1100,55 0 
     IKVAQGVSGAVQDK  1399,64 107 
     SLTQVR  703,42 17 
     AMMYSGELK  1045,56 8 
     TSSAQVEGGVHSLHSYEK  1915,89 10 
         
2098 MSMS Tapasin 302 14 LAPEYEAAATR 65 596,44 226 
     DGEEAGAYDGPR 57 618,88 194 
     ELSDFISYLQR 51 685,93 116 
     DLLIAYYDVDYEK 59 810,48 105 
     SDVLELTDDNFESR 70 820,48 128 
         
2888 MS 
Heparan sulfate 
glucosamine 3-O-
sulfotransferase 3A1 
69 52 QLPQAIIIGVKK  1307,67 130 
     GGTRALLEFLR  1232,6 89 
     AVGAEPHFFDR  1245,59 8 
     DLMPRTLDGQITMEK  1763,79 4 
     TLDGQITMEKTPSYFVTR  2102,73 142 
     ISAMSKDTK  996,55 50 
     AISDYTQTLSK  1226,78 81 
     AISDYTQTLSKRPDIPTFESLTFK  2758,24 68 
     TAGLIDTSWSAIQIGIYAK  2008,44 149 
     HLEHWLRHFPIR  1640,86 18 
     QMLFVSGER  1082,17 220 
     RIITDK  745,41 67 
     HFYFNK  855,15 17 
         
1906 MSMS Heat-Shock 70kd 
Protein  
130 9 TTPSYVAFTDTER 76 744,46 141 
     NQVALNPQNTVFDAK 54 830,04 132 
         
1600 MSMS Filamin A 155 1,5 AGNNMLLVGVHGPR 91 484,43 275 
     NGQHVASSPIPVVISQSEIG DASR 64 816,87 65 
         
  
Threonyl-tRNA 
synthetase 
110 5 NELSGALTGLTR 61 616,61 120 
  
   
QLENSLNEFGEKWELNSGDG 
AFYGPK 
49 971,56 65 
         
1893 MSMS 
Heat shock 70 kDa 
protein  
282 10 TTPSYVAFTDTER 77 744,46 141 
     NQVAMNPTNTVFDAK 69 830,04 132 
     IINEPTAAAIAYGLDR 81 844,52 77 
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     DAGVIAGLNVLR 55 599,46 183 
         
1845 MSMS Annexin A6 231 9 ALIEILATR 58 500,41 190 
     SELDMLDIR + Oxidation (M) 49 554,4 235 
     DAFVAIVQSVK 70 588,92 144 
     EDAQEIADTPSGDKTSLETR 54 721,75 106 
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Table 5: MS details of HCT-116 identified proteins     
Spot 
No. 
Id 
Method 
Protein name 
Mascot 
Protein 
Score 
Sequence 
coverage 
(%) 
Identified peptide sequence 
Single 
ion Score 
(MS/MS) 
Precursor 
mass 
(m/z) 
Mass error 
(ppm) 
4928 MSMS Peroxiredoxin-1  266 37 TIAQDYGVLK 49 554,42 207 
     
QITVNDLPVGR+ Pyro-glu (N-
term Q) 
49 597,95 209 
     GLFIIDDKGILR 45 454,03 206 
     QGGLGPMNIPLVSDPK 69 820,01 97 
     TIAQDYGVLKADEGISFR 54 661,84 247 
         
  Neuropolypeptide h3 194 18 LYTLVLTDPDAPSR 54 781,02 134 
     GNDISSGTVLSDYVGSGPPK 140 975,56 87 
         
2988 MSMS 
Heat shock protein 
90kDa alpha 
(cytosolic) 
112 3 EQVANSAFVER 49 625,18 208 
     GVVDSEDLPLNISR 63 757,53 178 
         
4323 MSMS 
Cell division control 
protein 42 homolog 
isoform 1 
96 19 NVFDEAILAALEPPEPK 48 618,31 86 
     TPFLLVGTQIDLRDDPSTIEK 48 786,9 190 
         
3826 MSMS 
Heat shock protein 
27  
167 18 QLSSGVSEIR 43 538,64 83 
     LFDQAFGLPR 75 582,64 51 
     VSLDVNHFAPDELTVK 49 595,7 72 
         
4018 MSMS 
Phosphoribosyltransf
erase domain-
containing protein 1  
157 16 NVLIVEDVVGTGR 87 685,96 109 
     
NDQSMGEMQIIGGDDLSTLAG
K + 2 Oxidation (M) 
70 771,49 86 
         
2989 MSMS  Annexin A1 397 29 TPAQFDADELR 87 632,09 120 
     GTDVNVFNTILTTR 71 776,3 71 
     SEDFGVNEDLADSDAR 106 870,73 143 
     MYGISLCQAILDETK 73 879,79 250 
     
GGPGSAVSPYPTFNPSSDVA 
ALHK 
60 786,6 106 
         
  
Heterogeneous 
nuclear 
ribonucleoprotein H3  
180 10 STGEAFVQFASK 53 636,58 180 
     DGMDNQGGYGSVGR 83 715,07 220 
     ATENDIANFFSPLNPIR 44 960,17 280 
         
4000 MSMS Peroxiredoxin-4 166 9 
QITLNDLPVGR + Pyro-glu (N-
term Q) 
54 604,97 223 
     LVQAFQYTDK 56 606,9 140 
     DYGVYLEDSGHTLR 56 813,01 154 
         
  Peroxiredoxin-6 101 12 LPFPIIDDR 50 543,4 92 
     
DGDSVMVLPTIPEEEAK+ 
Oxidation (M) 
51 923,24 216 
         
2941 MSMS 
Coproporphyrinogen 
oxidase  
375 32 FGLFTPGSR 50 491,39 265 
     YFEVEEADGNK 47 650,91 184 
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     YVEFNLLYDR 54 666,44 157 
 
 
   
IESILMSLPLTAR + Oxidation 
(M) 
46 730,5 130 
     AGVSISVVHGNLSEEAAK 59 590,13 254 
     ATSLGRPEEEEDELAHR 49 646.98 51 
     GIGGIFFDDLDSPSKEEVFR 70 1114,55 44 
         
 
 
Heterogeneous 
nuclear 
ribonucleoprotein C 
(C1/C2) 
234 16 SDVEAIFSK 45 498,37 231 
     KSDVEAIFSK 43 562,4 169 
     GFAFVQYVNER 54 665,43 143 
 
 
   
MIAGQVLDINLAAEPK+ 
Oxidation (M 
92 850,07 129 
 
 
       
3934 MSMS Actin beta 111 10 GYSFTTTAER 44 566,86 105 
     SYELPDGQVITIGNER 67 859,92 33 
         
  Enolase 109 9 
VVIGMDVAASEFFR + 
Oxidation (M) 
68 779,03 180 
     DATNVGDEGGFAPNILENK 41 981,04 76 
         
2903 MSMS Transaldolase 91 6 TIVMGASFR + Oxidation (M) 45 499,32 120 
     LLGELLQDNAK 46 607,42 123 
         
3578 MSMS 
Chloride intracellular 
channel protein 1  
251 33 GVTFNVTTVDTK 101 641,43 140 
     NSNPALNDNLEK 55 664,92 143 
 
 
   
VLDNYLTSPLPEEVDETSAEDE
GVSQR 
50 998,2 63 
 
 
   
VLDNYLTSPLPEEVDETSAEDE
GVSQRK 
45 1040,9 64 
         
1627 MSMS 
Heat shock cognate 
71 kDa protein 
isoform 1  
632 27 FEELNADLFR 48 627,41 159 
     TTPSYVAFTDTER 77 744,51 208 
 
 
   
SFYPEEVSSMVLTK  Oxidation 
(M) 
74 816,98 104 
 
 
   
NQVAMNPTNTVFDAK + 
Oxidation (M) 
82 833,52 96 
     LSKEDIER 48 495,38 232 
     VQVEYKGETK 50 590,94 212 
     DAGTIAGLNVLR 52 600,46 200 
     VEIIANDQGNR 66 614,94 195 
     NSLESYAFNMK 87 660,41 166 
     STAGDTHLGGEDFDNR 48 564,71 230 
         
2684 MSMS Septin 2  206 12 TIISYIDEQFER 67 757,18 264 
     TVQIEASTVEIEER 77 802,18 287 
     ASIPFSVVGSNQLIEAK 62 880,24 270 
         
1692 MSMS 
Succinate 
dehydrogenase 
complex, subunit A, 
flavoprotein (Fp) 
109 7 GEGGILINSQGER 43 665,41 105 
     IDEYDYSKPIQGQQK 66 906,56 127 
         
2351 MSMS keratin 18  166 7 IVLQIDNAR 49 521,6 19 
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     QSVENDIHGLR 43 626,08 130 
     AQIFANTVDNAR 74 660,59 190 
         
2761 MSMS 
Alcohol 
dehydrogenase 
[NADP+] 
399 22 ALEALVAK 68 407,68 184 
     SPAQILLR 43 449,2 178 
     YALSVGYR 45 464,66 194 
     GLVQALGLSNFNSR 75 738,12 232 
     VFDFTFSPEEMK 58 746,61 268 
     GLEVTAYSPLGSSDR 56 776,16 241 
     DPDEPVLLEEPVVLALAEK 54 1038,19 260 
         
1759 MS 
hsp70/hsp90 
organizing 
protein(HOP) 
93 23 WVNELKEK  1045,44 120 
     LDPHNHVLYSNR  1464,57 109 
     KAAALEFLNR  1132,51 123 
     TYEEGLKHEANNPQLK  1870,83 48 
     TLLSDPTYR  1065,44 112 
     ELIEQLR  900,49 22 
     ETKPEPMEEDLPENKK  1929,85 26 
     YKDAIHFYNK  1298,55 75 
     SLAEHR  712,3 98 
     SLAEHRTPDVLK  1365,3 51 
     LAYINPDLALEEK  1488,62 111 
     HYTEAIKR  1017,48 59 
     LILEQMQK  1002,49 70 
     LMDVGLIAIR  116,55 80 
         
2053 MSMS 
Phosphoglycerate 
dehydrogenase 
286 11 VTADVINAAEK 62 566,15 35 
     ILQDGGLQVVEK 77 650,15 154 
     GTIQVITQGTSLK 85 673,4 300 
     
TQTSDPAMLPTMIGLLAEAG 
VR 
62 768,84 290 
         
  
Inosine 
monophosphate 
dehydrogenase 
128 6 NLIDAGVDALR 69 579,24 69 
     YEQGFITDPVVLSPK 59 847,17 59 
         
2319 MSMS 
Fumarate hydratase 
precursor  
329 15 EYDTFGELK  61 607,85 90 
     AIEMLGGELGSK 73 610,67 237 
     VAALTGLPFVTAPNK 51 749,85 113 
     IYELAAGGTAVGTGLNTR 84 882,5 45 
     SGLGELILPENEPGSSIMPGK 60 1070,9 126 
         
1388 MSMS Chaperonin (HSP60) 87 8 AAVEEGIVLGGGCALLR 43 843,09 160 
     
TALLDAAGVASLLTTAEVVVTE
IPKEEK 
44 957,10 254 
         
2063 MS 
UDP-glucose 
dehydrogenase 
92 29 VTVVDVNESR 
 
1117,58 0 
     EADLVFISVNTPTK  1533,71 71 
     VLIGGDETPEGQR  1370,7 8 
     LAANAFLAQR  1074,6 10 
     DVLNLVYLCEALNLPEVAR  2201,18 9 
 98 
 
     IIDSLFNTVTDKK  1493,8 16 
     YLMDEGAHLHIYDPK  1817,88 27 
     EQIVVDLSHPGVSEDDQVSR  2209,13 8 
     MLKPAFIFDGR  1310,7 8 
     RIPYAPSGEIPK  1327,74 8 
     FSLQDPPNK  1045,54 0 
         
1421 MS lamin A/C isoform 3  212 44 SGAQASSTPLSPTR  1359,65 29 
     LQEKEDLQELNDR  1629,81 0 
     LAVYIDR  849,42 70 
     SLETENAGLR  1089,52 27 
     ITESEEVVSR  1148,56 17 
     AAYEAELGDAR  1165,53 16 
     TLEGELHDLR  1182,62 8 
     RVDAENR  859,4 46 
     LQTMKEELDFQK  1525,68 52 
     NIYSEELR  1023,5 9 
     LVEIDNGKQR  1171,6 17 
     LADALQELR  1028,54 29 
     AQHEDQVEQYKK  1502,67 33 
     NSNLVGAAHEELQQSR  1752,85 5 
     IRIDSLSAQLSQLQK  1699,84 17 
     LRDLEDSLAR  1187,63 8 
     
MQQQLDEYQELLDIKLALDMEI
HAYR 
 3223,2 186 
     LALDMEIHAYR  1347,63 29 
     LALDMEIHAYRK  1475,63 61 
     LLEGEEERLR  1243,67 8 
     VAVEEVDEEGKFVR  1605,79 12 
     QNGDDPLLTYR  1274,64 31 
     
ASASGSGAQVGGPISSGSSAS
SVTVTR 
 2365,14 8 
     SVGGSGGGSFGDNLVTR  1566,74 6 
         
2215 MS keratin8  237 42 SYTSGPGSR  911,41 11 
     ISSSSFSR  870,4 14 
     VGSSNFR  766,35 39 
     WSLLQQQK  1030,45 98 
     WSLLQQQKTAR  1358,57 100 
     SNMDNMFESYINNLR  1879,75 21 
     NKYEDEINK  1152,4 97 
     LEGLTDEINFLR  1419,66 63 
     QLYEEEIR  1062,4 94 
     ELQSQISDTSVVLSMDNSR  2108,93 37 
     SLDMDSIIAEVK  1336,58 20 
     AQYEDIANR  1079,42 51 
     SRAEAESMYQIK  1428,6 62 
     AEAESMYQIK  1185,46 73 
     YEELQSLAGK  1137,48 89 
     HGDDLR  712,3 87 
     TKTEISEMNR  1224,5 42 
     ASLEAAIADAEQR  1344,58 70 
     GELAIKDANAK  1129,52 74 
     EYQELMNVK  1169,46 68 
     LALDIEIATYR  1277,58 84 
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     LLEGEESR  932,4 64 
     LESGMQNMSIHTK  1507,61 53 
         
1466 MS Ezrin 127 28 PKPINVR  823,45 72 
     FYPEDVAEELIQDITQK  2038,16 70 
     
EGILSDEIYCPPETAVLLGSYAV
QAK 
 2823,66 88 
     SGYLSSER  898,37 59 
     DQWEDR  848,3 67 
     IQVWHAEHR  1175,58 80 
     IAQDLEMYGINYFEIK  1963,06 30 
     IGFPWSEIR  1104,55 29 
     KAPDFVFYAPR  1310,68 60 
     APDFVFYAPR  1182,58 43 
     RKPDTIEVQQMK  1488,8 89 
     AKEELER  874,4 90 
     SQEQLAAELAEYTAK  1651,85 32 
     QLLTLSSELSQAR  1445,77 17 
     THNDIIHNENMR  1509,72 39 
         
1207 MSMS 
KSRP /KH type-
splicing regulatory 
protein 
282 12 MMLDDIVSR 55 556,13 234 
     VPDGMVGLIIGR 48 621,72 201 
     LASQGDSISSQLGPIHPPPR 57 686,22 194 
     MILIQDGSQNTNVDKPLR 43 686,87 243 
     TSMTEEYRVPDGMVGLIIGR 79 752,52 240 
         
1401 MSMS Lamin A/C 668 23 LQEKEDLQELNDR. 44 815,51 122 
     MQQQLDEYQELLDIK 79 995,56 99 
     
ASASGSGAQVGGPISSGSSAS
SVTVTR 
81 1183,06 21 
     NSNLVGAAHEELQQSR 60 585,07 188 
     VAVEEVDEEGKFVR 57 803,51 124 
     SVGGSGGGSFGDNLVTR 87 783,99 140 
     
TALINSTGEEVAMR + 
Oxidation (M) 
68 754,47 126 
     LRDLEDSLAR 53 594,42 160 
     AAYEAELGDAR 68 583,35 120 
     LADALQELR 71 514,89 194 
         
3206 MSMS 
Cytosolic malate 
dehydrogenase  
104 8 LGVTANDVK 49 459,07 98 
     VIVVGNPANTNCLTASK 55 879,95 62 
         
1413 MS Ezrin 98 28 EVWYFGLHYVDNK  1669,69 59 
     VSAQEVR  788,32 65 
     FGDYNK  743,28 67 
     SGYLSSER  898,32 45 
     LIPQR  626,3 57 
     DQWEDR  848,31 65 
     IQVWHAEHR  1175,55 85 
     IAQDLEMYGINYFEIK  1963,06 30 
     IGFPWSEIR  1104,55 29 
     KAPDFVFYAPR  1310,68 15 
     APDFVFYAPR  1182,58 43 
     RKPDTIEVQQMK  1488,8 13 
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     ALQLEEER  987,46 23 
     AKEELER  874,4 39 
     SQEQLAAELAEYTAK  1651,85 18 
     IALLEEAR  914,5 21 
     QLLTLSSELSQAR  1445,7 25 
     THNDIIHNENMR  1509,7 41 
         
3112 MSMS Annexin A3 198 13 ALLTLADGR 50 465,29 32 
     SEIDLLDIR 56 537,3 9 
     GIGTDEFTLNR 46 611,95 237 
     SDTSGDYEITLLK 46 721,46 145 
         
  
Inoraganic 
pyrpohosphatase 
101 11 DKDFAIDIIK 54 589,45 212 
     VIAINVDDPDAANYNDINDVKR 47 815,48 90 
         
1563 MS Ezrin 99 24 PKPINVR  823,54 36 
     EVWYFGLHYVDNK  1669,84 23 
     SGYLSSER  898,47 18 
     DQWEDR  848,4 58 
     IQVWHAEHR  1175,63 17 
     IAQDLEMYGINYFEIK  1962,97 10 
     IGFPWSEIR  1104,61 27 
     KAPDFVFYAPR  1310,7 7 
     APDFVFYAPR  1182,62 25 
     RKPDTIEVQQMK  1488,8 13 
     AKEELER  874,49 34 
     SQEQLAAELAEYTAK  1651,85 18 
     IALLEEAR  914,5 21 
     QLLTLSSELSQAR  1445,82 13 
     THNDIIHNENMR  1509,74 33 
         
1432 MS Ezrin 87 18 PKPINVR  823,45 72 
     FYPEDVAEELIQDITQK  2038,16 70 
     IQVWHAEHR  1175,63 17 
     IGFPWSEIR  1104,61 27 
     KAPDFVFYAPR  1310,7 7 
     APDFVFYAPR  1182,62 25 
     RKPDTIEVQQMK  1488,8 13 
     QQLETEKK  1003,49 49 
     EKEELMLR  1063,52 28 
     QLLTLSSELSQAR  1445,82 13 
     THNDIIHNENMR  1509,74 33 
         
1399 MS Lamin A/C isoform 3  133 28 SGAQASSTPLSPTR  1359,65 29 
     LQEKEDLQELNDR  1629,81 0 
     SLETENAGLR  1089,52 27 
     EGDLIAAQAR  1043,37 95 
     TLEGELHDLR  1182,62 8 
     NIYSEELR  1023,5 9 
     LADALQELR  1028,54 29 
     NSNLVGAAHEELQQSR  1752,85 5 
     DLEDSLAR  918,4 54 
     IDSLSAQLSQLQK  1430,7 56 
     LALDMEIHAYR  1347,63 29 
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     QNGDDPLLTYR  1274,64 31 
     
ASASGSGAQVGGPISSGSSAS
SVTVTR 
 2365,14 8 
     SVGGSGGGSFGDNLVTR  1566,74 6 
         
1073 MSMS EEF2 93 3 VNFTVDQIR 43 546,39 174 
     VFSGLVSTGLK 50 554,4 135 
         
1673 MS Hsp70 171 32 AAAIGIDLGTTYSCVGVFQHGK  2265,18 22 
     VEIIANDQGNR  1228,56 81 
     TTPSYVAFTDTER  1487,68 13 
     IINEPTAAAIAYGLDR  1687,87 17 
     ATAGDTHLGGEDFDNR  1675,74 6 
     LVNHFVEEFK  1261,6 47 
     
TLSSSTQASLEIDSLFEGIDFYT
SITR 
 2981,56 33 
     ARFEELCSDLFR  1542,71 19 
     FEELCSDLFR  1315,54 18 
     LDKAQIHDLVLVGGSTR  1822 10 
     AQIHDLVLVGGSTR  1465,78 20 
     LLQDFFNGR  1109,5 63 
     
QTQIFTTYSDNQPGVLIQVYEG
ERAMTK 
 3216,37 55 
     ITITNDKGR  1017,51 59 
     LSKEEIER  1003,45 99 
     YKAEDEVQR  1137,47 61 
         
1433 MS Lamin A/C isoform 3  245 38 SGAQASSTPLSPTR  1359,65 29 
     LQEKEDLQELNDR  1629,81 0 
     SLETENAGLR  1089,52 27 
     ITESEEVVSR  1148,56 17 
     AAYEAELGDAR  1165,53 16 
     ARLQLELSK  1057,6 37 
     EAALSTALSEKR  1275,64 39 
     TLEGELHDLR  1182,62 8 
     NIYSEELR  1023,5 9 
     LVEIDNGKQR  1171,6 17 
     LADALQELR  1028,54 29 
     NSNLVGAAHEELQQSR  1752,81 28 
     IRIDSLSAQLSQLQK  1699,91 35 
     LALDMEIHAYR.  1347,62 37 
     LLEGEEERLR  1243,67 8 
     VAVEEVDEEGKFVR  1605,77 25 
     
ASASGSGAQVGGPISSGSSAS
SVTVTR 
 2365,1 25 
     SVGGSGGGSFGDNLVTR  1566,75 0 
         
1400 MS Lamin A/C isoform 3  283 49 SGAQASSTPLSPTR  1359,65 29 
     LQEKEDLQELNDR  1629,81 0 
     EDLQELNDR  1131,44 60 
     SLETENAGLR  1089,52 27 
     ITESEEVVSR  1148,56 17 
     AAYEAELGDAR  1165,53 16 
     VREEFK  807,36 99 
     EGDLIAAQA  1043,46 86 
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     TLEGELHDLR  1182,53 67 
     QLQDEMLRR  1187,53 32 
     RVDAENR  859,37 80 
     LQTMKEELDFQK  1525,68 52 
     NIYSEELR  1023,43 89 
     RHETR  698,3 100 
     AQHEDQVEQYKK  1502.77 3 
     NSNLVGAAHEELQQSR  1752,81 28 
     IRIDSLSAQLSQLQK  1699,91 35 
     MQQQLDEYQELLDIK  1909,98 31 
     LALDMEIHAYR.  1347,62 37 
     LLEGEEERLR  1243,67 8 
     ASSHSSQTQGGGSVTK  2365,07 38 
     SSFSQHAR  919,36 87 
     QNGDDPLLTYR  1274,61 7 
     
ASASGSGAQVGGPISSGSSAS
SVTVTR 
 2365,1 25 
     SVGGSGGGSFGDNLVTR  1566,75 0 
     TQSPQNCSIM  1165,5 0 
         
1445 MS Ezrin 171 33 PKPINVR    
     EVWYFGLHYVDNK  823,44 85 
     VSAQEVR  1669,84 23 
     FYPEDVAEELIQDITQK  788,32 65 
     SGYLSSER  2037,85 73 
     DQWEDR  898,47 18 
     IQVWHAEHR  848,4 58 
     IAQDLEMYGINYFEIK  1175,63 17 
     GTDLWLGVDALGLNIYEK  1962,97 10 
     IGFPWSEIR  1976,86 86 
     KAPDFVFYAPR  1104,61 27 
     APDFVFYAPR  1310,7 7 
     RKPDTIEVQQMK  1182,62 25 
     EKEELMLR  1488,8 13 
     ALQLEEER  1063,45 94 
     AKEELER  987,43 81 
     SQEQLAAELAEYTAK  874,39 80 
     QLLTLSSELSQAR  1651,85 18 
     THNDIIHNENMR  1445,82 13 
       1509,74 33 
1398 MS Lamin A/C isoform 3  238 35 SLETENAGLR    
     AAYEAELGDARK  1089,52 27 
     TLEGELHDLRGQVAK  1293,62 15 
     LQTMKEELDFQK  1665,82 42 
     NIYSEELRETK  1525,76 0 
     LADALQELR  1381,64 43 
     AQHEDQVEQYKK  1028,53 38 
     NSNLVGAAHEELQQSR  1502.77 3 
     IRIDSLSAQLSQLQK  1752,81 28 
     MQQQLDEYQELLDIK  1699,91 35 
     LALDMEIHAYR.  1909,98 31 
     SSFSQHAR  1347,62 37 
     VAVEEVDEEGKFVR  919,39 54 
     QNGDDPLLTYR  1605,77 25 
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ASASGSGAQVGGPISSGSSAS
SVTVTR 
 1274,61 7 
     SVGGSGGGSFGDNLVTR  2365,1 25 
     TQSPQNCSIM  1566,75 0 
       1165,5 0 
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                  Courses 
March 2010          
2D-DIGE Workshop (GE Healthcare), theoretical and practical course on 
differential proteomics at National Institute for Research and Treatment of 
Tumors ―G. Pascale‖, Naples, Italy 
 
August 2010 
Practical EMBO course titled: ―Post-translational modifications of 
proteins: from discovery to functional analysis‖. Uppsala, Sweden 
 
October 2011 
Awarded with a FEBS Youth Travel Fund (YTF) Fellowship to attend the 
FEBS Advanced Lecture Course on Translational Cancer 
Research, 27th September- 4th October 2011, Albufeira, Portugal 
 
 
Visiting appointment 
May-August 2010  
 
Short term fellowship during the PhD program under the supervision of 
Prof. M. Clench and Dr. S. Francese at the BMRC Institute (Biomedical 
Research Centre), Sheffield Hallam University, United Kingdom. 
Training on MALDI IMAGING MASS SPECTROMETRY 
 
Direct analysis of tissues of biological and clinical interest using MALDI 
MS has been shown to be successful for the study of the mid- to low 
molecular weight proteome. Because this technology analyzes intact 
tissue, avoiding homogenization and separation steps, the spatial 
distribution of molecules within the tissue is preserved. The process is 
relatively simple in that a matrix (typically a small aromatic organic 
molecule dissolved in an organic solvent) is deposited on top of a tissue 
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section followed by irradiation with a laser (e.g., nitrogen, 337 nm). 
Molecules are subsequently desorbed and ionized. 
MALDI is often coupled with TOF mass analyzers that allows a 
unlimited mass range is with analytes > 200 kDa capable of being 
measured. 
Image analysis of discrete molecules in tissue can be acquired by using 
MALDI MS to determine their spatial localization with a lateral resolution 
of 10–100 µm. A thin (10 µm) tissue section is collected on a target 
plate, and matrix is applied over the surface of the tissue by a robotic 
liquid dispensing device followed by desorption, ionization, and 
separation processes. Spectra are recorded in a systematic fashion 
over the tissue by moving the sample stage underneath a fixed laser 
beam. Thus, a spot array over the entire sample then constitutes the 
image dataset analogous to pixels in a digital photograph. Each laser-
irradiated spot (pixel) gives rise to a mass spectrum that is correlated to 
discrete a X,Y coordinate location on the tissue. Thus each spot or pixel 
contains a dataset having thousands of channels (m/z values) with each 
channel having its own brightness (intensity). The intensity of each m/z 
value can be expressed over the array of pixels as a 2D ion density 
map. Commercial or custom software can be used to generate images 
depicting the localization and relative intensities of hundreds of ions in a 
single acquisition from a tissue section. During the time spent in Dr 
Francese‘s laboratory at Sheffield Hallam University, UK, the above 
described experimental workflow was applied to coronal sections of 
mice brains. It was acquired good experience in this innovative field of 
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research. The following images show the distribution of phospholipid at 
m/z 826.4 in two different slices of a PKU brain as an example of the 
image obtained with MALDI imaging analysis followed by software 
elaboration of data. 
 
 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
m/z 826.4 m/z 826.4 
MALDI MS image of phospholipid at m/z 826.4 in two different slices of a PKU brain 
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